Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period ended June 30, 2024


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-56364

Charlotte's Web Holdings, Inc.

(Exact name of registrant as specified in its charter)


British Columbia									98-1508633
(State or other jurisdiction of incorporation or organization)									(I.R.S. Employer Identification No.)

700 Tech Court

Louisville, CO 80027

(Address of principal executive offices and zip code)

(720) 484-8930

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Securities registered pursuant to section 12(g) of the Act:

Common stock, no par value

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

The registrant had outstanding 157,495,042 shares of common shares as of August 6, 2024.

CHARLOTTE'S WEB HOLDINGS, INC.

FORM 10-Q

For the Quarter Ended June 30, 2024

TABLE OF CONTENTS




Part I	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)	2
	- Condensed Consolidated Balance Sheets	3
	- Condensed Consolidated Statements of Operations	4
	- Condensed Statements of Changes in Shareholders' Equity	5
	- Condensed Consolidated Statements of Cash Flows	6
	- Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3.	Quantitative and Qualitative Disclosures about Market Risk
Item 4.	Controls and Procedures

Part II	OTHER INFORMATION
Item 1.	Legal Proceedings
Item 1A.	Risk Factors
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.	Defaults Upon Senior Securities
Item 4.	Mine Safety Disclosures
Item 5.	Other Information
Item 6.	Exhibits

	SIGNATURES

PART I

Item 1. Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)


	June 30,		December 31,
	2024 (unaudited)		2023
ASSETS
Current assets:
Cash and cash equivalents	$	32,531	$	47,820
Accounts receivable, net	1,869		1,950
Inventories, net	18,673		21,538
Prepaid expenses and other current assets	3,857		6,864
Total current assets	56,930		78,172
Property and equipment, net	28,198		27,513
License and media rights	16,590		17,070
Operating lease right-of-use assets, net	13,740		14,601
Investment in unconsolidated entity	11,200		11,000
SBH purchase option and other derivative assets	1,436		2,602
Intangible assets, net	1,166		887
Other long-term assets	534		703
Total assets	$	129,794	$	152,548
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	4,350	$	2,860
Accrued and other current liabilities	6,669		8,682
Lease obligations – current	2,376		2,252
License and media rights payable - current	5,072		9,852
Total current liabilities	18,467		23,646
Convertible debenture	43,455		42,528
Lease obligations	14,456		15,655
License and media rights payable	14,093		11,338
Derivatives and other long-term liabilities	3,495		3,823
Total liabilities	93,966		96,990
Commitments and contingencies (Note 7)
Shareholders’ equity:
Common shares, nil par value; unlimited shares authorized; 157,495,042 and 154,332,366 shares issued and outstanding as of June 30, 2024 and December 31, 2023	1		1
Additional paid-in capital	328,241		327,280
Accumulated deficit	(292,414)		(271,723)
Total shareholders’ equity	35,828		55,558
Total liabilities and shareholders’ equity	$	129,794	$	152,548

See Notes to Unaudited Condensed Consolidated Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)


	Three Months Ended June 30, (unaudited)				Six Months Ended June 30, (unaudited)
	2024		2023		2024		2023
Revenue	$	12,289	$	16,006	$	24,413	$	33,016
Cost of goods sold	9,707		7,088		14,920		14,181
Gross profit	2,582		8,918		9,493		18,835

Selling, general and administrative expenses	14,727		19,627		30,007		37,140
Operating loss	(12,145)		(10,709)		(20,514)		(18,305)

Gain on initial investment in unconsolidated entity	—		10,700		—		10,700
Change in fair value of financial instruments	1,140		4,229		(720)		9,612
Other income (expense), net	(6)		(1,376)		605		(2,074)
Income (loss) before provision for income taxes	(11,011)		2,844		(20,629)		(67)
Income tax benefit (expense)	(46)		—		(62)		—
Net income (loss)	$	(11,057)	$	2,844	$	(20,691)	$	(67)

Per common share amounts (Note 10)
Net income (loss) per common share, basic	$	(0.07)	$	0.02	$	(0.13)	$	—
Net income (loss) per common share, diluted	$	(0.07)	$	0.02	$	(0.13)	$	—

See Notes to Unaudited Condensed Consolidated Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands, except share amounts)

(unaudited)


	Common Shares			Additional Paid-in Capital		Accumulated Deficit		Total Shareholders’ Equity
	Shares	Amount
Balance—December 31, 2023	154,332,366	$	1	$	327,280	$	(271,723)	$	55,558
Common shares issued upon vesting of restricted share units, net of withholding	2,895,489	—		(98)		—		(98)
Share-based compensation	—	—		842		—		842
Net income (loss)		—				(9,634)		(9,634)
Balance— March 31, 2024	157,227,855	$	1	$	328,024	$	(281,357)	$	46,668
Common shares issued upon vesting of restricted share units, net of withholding	267,187	—		(20)		—		(20)
Share-based compensation	—	—		237		—		237
Net income (loss)	—	—		—		(11,057)		(11,057)
Balance—June 30, 2024	157,495,042	$	1	$	328,241	$	(292,414)	$	35,828

Balance—December 31, 2022	152,135,026	$	1	$	325,431	$	(247,927)	$	77,505
Common shares issued upon vesting of restricted share units, net of withholding	297,888	—		(69)		—		(69)
Share-based compensation	—	—		375		—		375
Net income (loss)	—	—		—		(2,912)		(2,912)
Balance—March 31, 2023	152,432,914	$	1	$	325,737	$	(250,839)	$	74,899
Common shares issued upon vesting of restricted share units, net of withholding	392,204	—		(6)		—		(6)
Share-based compensation	—	—		624		—		624
Net income (loss)	—	—		—		2,844		2,844
Balance—June 30, 2023	152,825,118	$	1	$	326,355	$	(247,995)	$	78,361

See Notes to Unaudited Condensed Consolidated Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)


	Six Months Ended June 30, (unaudited)
	2024		2023

Cash flows from operating activities:
Net loss	$	(20,691)	$	(67)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,982		7,769
Inventory provision	3,926		320
Convertible debenture accrued interest	1,931		1,954
Share-based compensation	1,079		999
Changes in right-of-use assets	908		976
Change in fair value of financial instruments	720		(9,612)
Gain on investment in unconsolidated entity	—		(10,700)
(Gain)/loss on foreign currency transaction	(1,430)		979
Other	238		957
Changes in operating assets and liabilities:
Accounts receivable, net	(154)		(1,104)
Inventories, net	(1,025)		2,878
Prepaid expenses and other current assets	1,732		764
Accounts payable, accrued and other liabilities	(286)		183
Operating lease obligations	(1,121)		(1,436)
License and media rights	(2,500)		(4,000)
Income taxes receivable	—		4,261
Other operating assets and liabilities, net	(192)		(130)
Net cash used in operating activities	(11,883)		(5,009)
Cash flows from investing activities:
Purchases of property and equipment and intangible assets	(3,316)		(187)
Proceeds from sale of assets	28		36
Net cash used in investing activities	(3,288)		(151)
Cash flows from financing activities:
Other financing activities	(118)		(75)
Net cash used in financing activities	(118)		(75)
Net decrease in cash and cash equivalents	(15,289)		(5,235)
Cash and cash equivalents —beginning of period	47,820		66,963
Cash and cash equivalents —end of period	$	32,531	$	61,728
Non-cash activities:
Non-cash purchase of property and equipment and intangible assets	(269)		(163)
Non-cash issuance of note receivable	—		(156)

See Notes to Unaudited Condensed Consolidated Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

1. DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS

Description of the Business

Charlotte's Web Holdings, Inc. together with its subsidiaries (collectively "Charlotte's Web" or the "Company") is a public company incorporated pursuant to the laws of the Province of British Columbia and a Certified B Corp. The Company's common shares are publicly listed on the Toronto Stock Exchange ("TSX") under the symbol "CWEB" and quoted on the OTCQX under the symbol "CWBHF." The Company's corporate headquarters is located in Louisville, Colorado in the United States of America. The majority of the Company's business is conducted in the United States of America.

The Company's primary products are made from proprietary strains of whole-plant hemp extracts containing a full spectrum of phytocannabinoids, terpenes, flavonoids and other hemp compounds. Hemp extracts are produced from the plant Cannabis sativa L. ("Cannabis"), and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol ("THC") concentration of not more than 0.3% on a dry weight basis ("Hemp"). The Company is engaged in research involving the effectiveness of a broad variety of compounds derived from Hemp. The Company does not currently produce or sell medical or recreational marijuana or products derived from high THC Cannabis plants. The Company does not currently have any plans to expand into such high THC products in the near future.

The Company's current product categories include full spectrum hemp extract oil tinctures (liquid product), gummies, capsules, soft-gels, CBD topical creams and lotions, and pet products. The Company's products are distributed through its e-commerce website, third-party e-commerce websites, select distributors, health practitioners, and a variety of brick-and-mortar specialty retailers.

The Company grows its proprietary hemp domestically in the United States on farms leased in northeastern Colorado and sources hemp through contract farming operations in Arizona, Colorado, Kentucky, Oregon, and Canada. The Hemp grown in Canada is utilized exclusively in the Canadian markets or for research purposes and not in products sold within the United States.

In furtherance of the Company's research and development ("R&D") efforts, the Company established CW Labs, an internal division for R&D, to expand the Company's efforts around the science of hemp derived compounds. CW Labs is currently engaged in clinical trials addressing Hemp-based health solutions. CW Labs is located in Louisville, Colorado at the Company's current good manufacturing practice ("cGMP") production and distribution facility.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB").

In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company's financial position as of June 30, 2024 and its results of operations for the three and six months ended June 30, 2024 and 2023, cash flows for the six months ended June 30, 2024 and 2023, and stockholders' equity for the three and six months ended June 30, 2024 and 2023. Operating results for the three and six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024. The unaudited interim condensed consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual consolidated financial statements. Certain amounts presented in prior periods have been reclassified to conform with the current period presentation. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2024.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

Inventories

Inventories are stated at the lower of cost or net realizable value. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. The Company's inventory production process for cannabinoid products includes the cultivation of botanical raw material. Due to the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset.

Revenue Recognition

The majority of the Company's revenue is derived from sales of branded products to consumers via the Company's direct-to-consumer e-commerce website, as well as distributors, retail and wholesale business-to-business customers. Additionally, on February 12, 2024, the Company and DeFloria LLC ("DeFloria") entered into a Master Services Agreement ("Services Agreement") pursuant to which the Company is compensated for the provision of certain services to DeFloria. Refer to Note 3 for additional disclosure on the DeFloria Service Agreement. The following table sets forth the disaggregation of the Company's revenue:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Direct-to-consumer	$	7,820	$	10,734	$	15,592	$	22,002
Business-to-business	4,395		5,272		8,436		11,014
Service revenue	74		—		385		—
Total	$	12,289	$	16,006	$	24,413	$	33,016

Substantially all of the Company's revenue is earned in the United States.

Recently Adopted Accounting Pronouncements

There are no new recent accounting pronouncements that have been issued by the Financial Accounting Standards Board ("FASB") and adopted by the Company had or may have a material impact on the accompanying unaudited interim condensed consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

Other than described below, no new accounting pronouncements issued by the FASB may have a material impact on the Company's consolidated financial statements and related disclosures.

On December 14, 2023, the FASB issued a final standard on improvements to income tax disclosures, ASU 2023-09, Improvements to Income Tax Disclosures. The standard requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. For public business entities, the new requirements will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact, if any, that the updated standard will have on the Company's consolidated financial statements and related disclosures.

On November 27, 2023, the FASB issued ASU 2023-07—Segment Reporting. The new guidance was issued primarily to provide financial statement users with more disaggregated expense information about a public entity's reportable segments. The guidance is effective for calendar year public entities in 2024 year-end financial statements and should be adopted retrospectively unless impracticable. The Company is currently evaluating the impact, if any, that the updated standard will have on the Company's consolidated financial statements and related disclosures.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

3. FAIR VALUE MEASUREMENT

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023, by level within the fair value hierarchy:


	June 30, 2024
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	745	$	745
Debt interest rate conversion feature	—		—		691		691
Total financial assets	$	—	$	—	$	1,436	$	1,436

Investment in unconsolidated entity:	$	—	$	—	$	11,200	$	11,200

Financial liabilities:
Debt conversion option	$	—	$	2,892	$	—	$	2,892


	December 31, 2023
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	1,730	$	1,730
Debt interest rate conversion feature	—		—		872		$	872
Total financial assets	$	—	$	—	$	2,602	$	2,602

Investment in unconsolidated entity:	$	—	$	—	$	11,000	$	11,000

Financial liabilities:
Debt conversion option	$	—	$	3,213	$	—	3,213

There were no transfers between levels of the fair value hierarchy during the three and six month periods ended June 30, 2024 and the year ended December 31, 2023.

Investment in Unconsolidated Entity

On April 6, 2023, the Company jointly formed an entity, DeFloria, with AJNA BioSciences PBC ("AJNA"), and a subsidiary of British American Tobacco PLC (LSE: BATS and NYSE: BTI) ("BAT"). AJNA is a botanical drug development company. AJNA is partially owned and was co-founded by a co-founder of Charlotte's Web. The entity was established to pursue FDA-approval for a botanical drug to target a neurological condition.

BAT holds an equity interest in DeFloria in the form of 200,000 or 100% preferred units following its $10 million initial investment and has the right to participate in future equity issuances to maintain its pro rata equity position. In 2024, BAT and AJNA invested an additional $5 million and $2 million, respectively, into DeFloria in exchange for a convertible debenture. The Company and AJNA each hold 400,000 or approximately 50%, respectively, of DeFloria's voting common units. The Company's contribution to DeFloria is a license permitting the use of certain proprietary hemp intellectual property, including clinical and consumer data. Additionally, the Company has a supply agreement with DeFloria, under which the Company supplies the oils at cost used to produce and develop the new drug. AJNA's contribution to the entity is laboratory and regulatory services, clinical expertise, and the provision of clinical services. DeFloria is

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

expected to use the investments for the clinical development of a hemp botanical Investigational New Drug application and has commenced Phase I clinical development.

Concurrently with the formation of DeFloria, the Company was issued a warrant to purchase 865,052 shares of Class A Common Stock of AJNA for an exercise price of $2.89 per share. Management determined the warrant should be accounted for in accordance with ASC 321, which requires the warrant to be measured at fair value at issuance and subsequently remeasured at fair value each reporting period. All changes from the remeasurement of the warrant will be recorded as a change in fair value of financial instruments in the condensed consolidated statements of operations. The Company determined the fair value of the AJNA warrants to be de minimis and as such no value was recorded as of June 30, 2024.

The Company determined that it has a variable interest in the investment in DeFloria; however, the Company is not the primary beneficiary of DeFloria as it lacks the power to direct DeFloria's key activities. The Company concluded that the investment in DeFloria should not be consolidated. The maximum exposure to loss in the investment in DeFloria is limited to the Company's investment, which is represented by the financial statement carrying amount of its retained interest.

In accordance with ASC 825-10, equity method investments are eligible for the fair value option as they represent recognized financial assets. As the Company is not required to consolidate the investment and does not meet any of the other scope exceptions, the Company had the ability to adopt the fair value option for the investment at inception. Upon formation of the entity, the Company elected the fair value option because it allowed the investment to be valued based on current market conditions. For the three and six month ending June 30, 2023, the Company recognized a gain for the initial investment in DeFloria of $10,700 within gain on initial investment in unconsolidated entity in the condensed consolidated statements of operations.

The investment has been remeasured at fair value at each reporting date, with changes recognized in condensed consolidated statements of operations as changes in fair value of financial instruments for the period. For the three months ended June 30, 2024 and June 30, 2023, a gain of $1,000 and $0, respectively, related to the investment in DeFloria was recognized as a change in fair value of financial instruments in the condensed consolidated statements of operations. Additionally, for the six months ended June 30, 2024 and June 30, 2023, a gain of $200 and $0, respectively, related to the investment in DeFloria was recognized as a change in fair value of financial instruments in the condensed consolidated statements of operations. As of June 30, 2024 and December 31, 2023, the DeFloria investment represents an investment of $11,200 and $11,000, respectively, within the condensed consolidated balance sheets.

The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. To determine the value of the investment, the Company utilizes an Option Pricing Model (OPM). The OPM considers the various terms of the stockholder agreements, including the level of seniority among the securities, dividend policy, conversion ratios, and cash allocations upon liquidation of the entity. The OPM is appropriate when the range of potential future outcomes is difficult to predict with any certainty.

The following additional assumptions are used in the model:


	June 30,	December 31,
	2024	2023
Expected term (years)	5.8	6.3
Volatility	77.0%	70.0%
Risk-free interest rate	4.3%	3.9%
Expected dividend yield	—%	—%
Discount for lack of marketability	31.0%	20.0%

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

Convertible Debt Derivatives

On November 14, 2022, the Company entered into a subscription agreement (the "Subscription Agreement") with BT DE Investments, Inc. a wholly-owned subsidiary of BAT Group (LSE: BATS and NYSE: BTI) (the "Lender"), providing for the issuance of $56.8 million (C$75.3 million) convertible debenture (the "debenture"). The debenture is convertible into 19.9% ownership of the Company's common shares at a conversion price of C$2.00 per common share of the Company on the TSX. The debenture will accrue interest at a stated annualized rate of 5% until such time that there is federal regulation permitting the use of cannabidiol, a phytocannabinoid derived from the plant Cannabis sativa L. ("CBD") as an ingredient in food products and dietary supplements in the United States. (The term "federal regulation" is defined as the date that federal laws in the United States permit, authorize or do not prohibit the use of CBD as an ingredient in food products and dietary supplements). Following federal regulation of CBD, the annualized rate of interest shall reduce to 1.5%. The maturity date for the debenture is November 14, 2029 (the "Maturity Date").

Debt Interest Rate Conversion Feature

The debt interest rate conversion feature is classified as a financial asset and is remeasured at fair value at each reporting date, with changes recognized in condensed consolidated statements of operations as changes in fair value of financial instruments for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. The debt interest rate conversion feature, if triggered, reduces the stated interest rate of the debenture to 1.5% upon federal regulation of CBD in the United States.

For the three months ended June 30, 2024 and June 30, 2023, a loss of $101 and a gain of $106, respectively, related to the debt interest rate conversion feature was recognized as a change in fair value of financial instruments in the condensed consolidated statements of operations. Additionally, for the six months ended June 30, 2024 and June 30, 2023, a loss of $154 and $506, respectively, related to the debt interest rate conversion feature was recognized as a change in fair value of financial instruments in the condensed consolidated statements of operations. As of June 30, 2024 and December 31, 2023, the debt interest rate conversion feature represents a financial asset of $691 and $872, respectively, within SBH purchase option and other derivative assets in the condensed consolidated balance sheets.

To determine the value of the debt interest rate conversion feature, the Company utilizes a probability weighted income approach. This method calculates the present value of the reduced interest accrued on the debenture assuming the feature is triggered at a certain time, after accounting for the probability of federal regulation of CBD. This approach is useful when ultimate valuation is based on an unverifiable outcome, such as an event outside of the Company's influence. The following additional assumptions are used in the model:


	June 30,	December 31,
	2024	2023
Stated interest rate	5.0%	5.0%
Adjusted interest rate	1.5%	1.5%
Implied debt yield	16.3%	11.0%
Federal regulation probability	Various	Various
Year of event	Various	Various

Debt Conversion Option

Per the debenture, the Lender has the option, at any time before the Maturity Date at no additional consideration, for all or any part of the principal amount to be converted into fully paid and non-assessable common shares. The Company assessed this conversion feature and determined that the debt conversion option is an embedded derivative that requires bifurcation and is classified as a financial liability. The debt conversion option is initially measured at fair value and is revalued at each reporting period using the Black-Scholes option pricing model based on Level 2 observable inputs. The assumptions used by the Company are the quoted price of the Company's common shares in an active market, risk-free interest rate, volatility and expected life, and assumes no dividends. Volatility is based on the actual historical market activity of the Company's shares. The expected life is based on the remaining contractual term of the debenture and the risk-free

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

interest rate is based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the expected maturity of the debenture.

For the three months ended June 30, 2024 and June 30, 2023, a gain of $276 and $4,066, respectively, related to the debt conversion option was recognized as a change in fair value of financial instruments in the condensed consolidated statements of operations. For the six months ended June 30, 2024 and June 30, 2023, a gain of $220 and $10,361, respectively, related to the debt conversion option was recognized as a change in fair value of financial instruments in the statements of operations. As of June 30, 2024 and December 31, 2023, the debt conversion option represents a financial liability of $2,892 and $3,213, respectively, within derivative and other long-term liabilities in the condensed consolidated balance sheets.

The following table provides the assumption regarding Level 2 fair value measurements inputs at their measurement dates:


	June 30,	December 31,
	2024	2023
Expected volatility	88.0%	87.4%
Expected term (years)	5.4	5.9
Risk-free interest rate	4.3%	3.9%
Expected dividend yield	—%	—%
Value of underlying share	C$0.27	C$0.27
Exercise price	C$2.00	C$2.00

Stanley Brothers USA Holdings Purchase Option

In 2021, the Company entered into an option purchase agreement (the "SBH Purchase Option") with Stanley Brothers USA Holdings, Inc ("Stanley Brothers USA"). The SBH Purchase Option was purchased for total consideration of $8,000 and has a term of five years (extendable for an additional two years upon payment of additional consideration). The SBH Purchase Option provides the Company the option to acquire all or substantially all the shares of Stanley Brothers USA at a purchase price to be determined at the time of exercise of the SBH Purchase Option. Upon exercise of the SBH Purchase Option, the purchase price will be determined based on application of predetermined multiples of Stanley Brothers USA revenue and earnings before interest, taxes, depreciation, and amortization ("EBITDA") measures. The Company is not obligated to exercise the SBH Purchase Option. As part of the SBH Purchase Option agreement, Stanley Brothers USA issued the Company a warrant exercisable to purchase 10% of the outstanding Stanley Brothers USA shares and convertible securities that are considered in-the-money, subject to certain conditions and exclusions. The warrant is exercisable at the Company's election for a nominal exercise price in the event the Company elects not to acquire all or substantially all shares of Stanley Brothers USA and expires 60 days after the expiration of the option.

The Company elected the fair value option in accordance with ASC 825-10 guidance to record its SBH Purchase Option. The SBH Purchase Option is classified as a financial asset and is remeasured at fair value at each reporting date, with changes to fair value recognized in the condensed consolidated statements of operations for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows. For the three months ended June 30, 2024 and June 30, 2023, a loss of $34 and a gain of $57, respectively, related to the SBH Purchase Option was recognized as change in fair value of financial instruments in the statements of operations. For the six months ended June 30, 2024 and June 30, 2023, a loss of $985 and $243, respectively, related to the SBH Purchase Option was recognized as change in fair value of financial instruments in the condensed consolidated statements of operations. As of June 30, 2024 and December 31, 2023, the SBH Purchase Option represents a financial asset of $745 and $1,730, respectively, within SBH purchase option and other derivative assets in the condensed consolidated balance sheets.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

The Monte Carlo valuation model considers multiple revenue and EBITDA outcomes for Stanley Brothers USA and other probabilities in assigning a fair value. Primary assumptions utilized include financial projections of Stanley Brothers USA and the probability and timing of exercise. The following additional assumptions are used in the fair value model of the SBH Purchase Option:


	June 30,	December 31,
	2024	2023
Expected volatility	125.0%	125.0%
Expected term (years)	1.7	2.2
Risk-free interest rate	4.9%	4.2%
Weighted average cost of capital	51.8%	50.6%

4. INVENTORIES

Inventories consist of the following:


	June 30,		December 31,
	2024		2023
Harvested hemp and seeds	$	8,009	$	9,300
Raw materials	12,153		9,726
Finished goods	5,751		6,320
	25,913		25,346
Less: inventory provision	(7,240)		(3,808)
Total inventory	$	18,673	$	21,538

Inventory Provision

For the six months ended June 30, 2024, inventory provisions of $3,926 were expensed through cost of goods sold in the condensed consolidated statements of operations. The increase in the inventory provision was primarily due to the revaluation on aged hemp based on current market conditions.

5. LICENSE AND MEDIA RIGHTS

MLB Promotion Rights Agreement

On October 11, 2022, the Company entered into a Promotional Rights Agreement (the "MLB Promotional Rights Agreement") with MLB Advanced Media L.P., on its own behalf and on behalf of Major League Baseball Properties, Inc., the Office of the Commissioner of Baseball, The MLB Network, LLC and the Major League Baseball Clubs (collectively, the "MLB"), pursuant to which the Company entered into a strategic partnership with MLB to promote the Company’s new NSF-Certified for Sport® product line. On January 29, 2024, the Company and MLB entered into the First Amendment to the Promotional Rights Agreement ("First Amendment"). The First Amendment extended the agreement through December 31, 2027, with an aggregate rights fee of $23 million for the remainder of the term.

As consideration under the MLB promotional rights agreement, the Company has paid and is committed to pay a combination of cash over the license period, along with upfront non-cash consideration in the form of equity, as well as contingent consideration in the form of contingent payments based on revenue.

As of June 30, 2024 and December 31, 2023, the carrying value of the licensed properties was $13,640 and $14,589, respectively, recorded as a license and media rights asset within the condensed consolidated balance sheets. As of June 30, 2024 and December 31, 2023, the

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

carrying value of the media rights was $3,950 and $4,982 recorded as a prepaid asset and a license and media rights asset within the condensed consolidated balance sheets. For the three months ended June 30, 2024 and June 30, 2023, the Company paid MLB $0 and $2,000, respectively, as part of the committed cash payments, and recognized $1,025 and $2,074, respectively, in amortization expense related to the license and media right assets. For the six months ended June 30, 2024 and June 30, 2023, the Company paid MLB $2,500 and $4,000, respectively, as part of the committed cash payments, and recognized $1,999 and $3,897, respectively, in amortization expense related to the license and media right assets. Licensed properties are amortized straight line and media rights are amortized as incurred.

The MLB First Amendment agreement extended the maturities of the future payment by an additional 2 years. Maturities of the MLB license and media rights payable as of June 30, 2024 are as follows:


2024 (6 months remaining)	$	2,500
2025	5,500
2026	6,000
2027	6,500
Total payments	$	20,500
Less: Imputed interest	(1,335)
Total license and media rights payable	$	19,165
Less: Current license liabilities	(5,072)
Total non-current license and media rights payable	$	14,093

As of June 30, 2024, expected amortization of licensed properties are as follows:


2024 (6 months remaining)	$	1,949
2025	3,897
2026	3,897
2027	3,897
Total future amortization	$	13,640

6. DEBT

Convertible Debenture

On November 14, 2022, the Company entered into the Subscription Agreement with BT DE Investments, Inc., providing for the issuance of a $56.8 million (C$75.3 million) convertible debenture. The debenture was denominated in Canadian Dollars ("CAD" or "C$"). The debenture is convertible into 19.9% ownership of the Company’s common shares at a conversion price of C$2.00 per common share of the Company. The debenture will accrue interest at a stated annualized rate of 5% until such time that there is federal regulation permitting the use of CBD as an ingredient in food products and dietary supplements in the United States. Following federal regulation of CBD, the stated annualized rate of interest shall reduce to 1.5%. The maturity date for the debenture is November 14, 2029.

The following is a summary of the Company's convertible debenture as of June 30, 2024:


	As of June 30, 2024
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	59,668	$	(16,213)	$	43,455

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

The following is a summary of the Company's convertible debenture as of December 31, 2023:


	As of December 31, 2023
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	60,116	$	(17,588)	$	42,528

The debenture was C$75.3 million per the subscription agreement and translated to USD on the transaction date. For the three months ended June 30, 2024 and June 30, 2023, the Company recognized a foreign currency gain of $430 and a loss of $831, respectively, related to the net carrying value of the debenture within the condensed consolidated statement of operations. Additionally, for the six months ended June 30, 2024 and June 30, 2023, the Company recognized a foreign currency gain of $1,355 and a loss of $820, respectively, related to the net carrying value of the debenture within the condensed consolidated statement of operations.

Interest is accrued annually and payable on the maturity date or date of earlier conversion. On conversion, accrued interest will either be converted into common shares equal to the amount of accrued interest or will be paid in cash if agreed with the Lender. As of June 30, 2024 and June 30, 2023, the principal amount of the debenture includes $4,636 and $1,777, respectively, of accrued interest expense. The following is a summary of the interest expense and amortization expense, recorded within the statement of operation, of the Company's convertible debenture for the three and six months ended June 30, 2024 and June 30, 2023:


	Three Months Ended June 30,				Six Months Ended June 30,
Interest and Amortization Expense	2024		2023		2024		2023
Interest expense	$	721	$	701	$	1,454	$	1,398
Amortization of debt discounts and costs	427		349		828		668
Total	$	1,148	$	1,050	$	2,282	$	2,066

7. COMMITMENTS AND CONTINGENCIES

Legal Contingencies

From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of June 30, 2024 there is no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company’s financial position, results of operations or cash flows.

8. LEASES

The Company has lease arrangements related to office space, warehouse and production space, and land to facilitate agricultural operations. The leases have remaining lease terms of less than one to eleven years, some of which include options to extend the leases for up to five years. Generally, the lease agreements do not include options to terminate the lease.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

Maturities of operating lease liabilities as of June 30, 2024 are as follows:


	Operating Leases
2024 (6 months remaining)	$	1,640
2025	2,892
2026	2,169
2027	1,844
2028	1,762
Thereafter	11,884
Total lease obligation	22,191
Less: Imputed interest	(5,359)
Total lease liabilities	16,832
Less: Current lease liabilities	(2,376)
Total non-current lease liabilities	$	14,456

9. SHAREHOLDERS’ EQUITY

As of June 30, 2024 and December 31, 2023, the Company’s share capital consists of one class of issued and outstanding shares: common shares. The Company is also authorized to issue preferred shares issuable in series. To date, no shares of preferred shares have been issued or are outstanding.

Common Shares

As of June 30, 2024 and December 31, 2023, the Company was authorized to issue an unlimited number of common shares, which have no par value.

10. INCOME (LOSS) PER SHARE

The Company computes income (loss) per share of common shares. Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding. Diluted income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares together with the number of additional common shares that would have been outstanding if all potentially dilutive common shares had been issued, unless anti-dilutive.

The following table sets forth the computation of basic and dilutive net income (loss) per share attributable to common shareholders:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Net income (loss)	$	(11,057)	$	2,844	$	(20,691)	$	(67)
Weighted-average number of common shares - basic	157,227,855		152,481,470		156,632,263		152,398,273
Dilutive effect of securities	—		278,618		—		—
Weighted-average number of common shares - diluted	157,227,855		152,760,088		156,632,263		152,398,273
Income (loss) per common share – basic	$	(0.07)	$	0.02	$	(0.13)	$	—
Income (loss) per common share – diluted	$	(0.07)	$	0.02	$	(0.13)	$	—

As of June 30, 2024 and June 30, 2023, potentially dilutive securities include stock options, restricted share units, and convertible debenture conversion. When the Company recognizes a net loss from continuing operations, all potentially dilutive shares are anti-dilutive

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

and are consequently excluded from the calculation of diluted net loss per share. As such, for the three and six months ended June 30, 2024 and for the six months ended June 30, 2023, all potentially dilutive shares have been excluded. When the Company recognizes net income from continuing operations, the Company computes the effect of dilutive securities using the treasury stock method and average market prices during the period.


	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Outstanding options	4,523,486	7,012,707	4,523,486	7,012,707
Outstanding restricted share units	5,583,322	2,398,844	5,583,322	2,677,462
Total	10,106,808	9,411,551	10,106,808	9,690,169

The Company's debenture is convertible into 19.9% ownership of the Company’s common shares at a conversion price of C$2.00 per common share of the Company. The Company can settle the convertible debenture in shares. If the convertible debenture in diluted EPS is anti-dilutive, or if the conversion value of the debenture does not exceed their conversion price for a reporting period, then the shares underlying the notes will not be reflected in the Company’s calculation of diluted EPS. For the three and six months ended June 30, 2024 and June 30, 2023, the price of the Company’s Shares did not exceed the conversion price and therefore there was no impact to diluted EPS during those periods.

11. SHARE-BASED COMPENSATION

Stock options

Stock options vest over a prescribed service period and are approved by the Company's board of directors on an award-by-award basis. Options have a prescribed service period generally lasting up to four years, with certain options vesting immediately upon issuance. Upon the exercise of any stock options, the Company issues shares to the award holder from the pool of authorized but unissued common shares.

There were no options granted for the six months ended June 30, 2024. The fair values of options granted for the six months ended June 30, 2023 were determined using a Black-Scholes model. The following principal inputs were used in the valuation of awards issued for the six months ended June 30, 2023:


									Six Months Ended June 30,
									2023
Expected volatility									88.8%
Expected term (years)									5.5-6.5
Risk-free interest rate									3.4%
Expected dividend yield									0%
Value of underlying share									$0.36

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

Detail of the number of stock options outstanding for the six months ended June 30, 2024 under the Company's 2015 legacy option plan and the Company's amended 2018 long term incentive plan (collectively, the "Plans") is as follows:


	Number of Options	Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contract Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	5,780,134	$	0.75	8.56	$	—
Granted	—	—
Exercised	—	—
Forfeited (and expired)	(1,256,648)	0.50
Outstanding as of June 30, 2024	4,523,486	$	0.83	7.94	$	—

Exercisable/vested as of June 30, 2024	3,442,986	$	0.89	7.69	$	—

There were no options granted during the six months ended June 30, 2024. The weighted average grant-date fair value of options granted during the six months ended June 30, 2023 was $0.38.

There were no options exercised during the six months ended June 30, 2024 and 2023.

Restricted share units

The Company has issued time-based restricted share units to certain employees as permitted under the 2018 long term incentive plan ("the 2018 Plan"). The restricted share units granted vest in accordance with the board-approved agreement, typically over equal installments up to four years. Upon vesting, one share of the Company’s common shares is issued for each restricted share unit awarded. The fair value of each restricted share unit granted is equal to the market price of the Company’s shares at the date of the grant. The fair value of shares vested during the six months ended June 30, 2024 and 2023 was $946 and $872, respectively.

Details of the number of restricted share units outstanding under the 2018 Plan is as follows:


	Number of Shares	Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2023	7,250,766	$	0.31
Granted	3,021,276	$	0.21
Forfeited	(898,685)	$	0.24
Vested	(3,162,676)	$	0.30
Shares withheld upon vesting	(627,359)	$	0.49
Outstanding as of June 30, 2024	5,583,322	$	0.26

Share-based Compensation Expense

Share-based compensation expense for all equity arrangements for the three months ended June 30, 2024 and 2023 was $237 and $624, respectively, included in selling, general and administrative expense in the condensed consolidated statements of operations. Share-based

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

( In thousands, except share, per share, per unit, and number of years)

(unaudited)

compensation expense for all equity arrangements for the six months ended June 30, 2024 and 2023 was $1,079 and $999, respectively, included in selling, general and administrative expense in the condensed consolidated statements of operations.

As of June 30, 2024, $2,776 of total unrecognized share-based compensation expense related to unvested options and restricted stock units granted to employees is expected to be recognized over a weighted-average period of 2.17 years.

12. INCOME TAXES

The Company reported income tax expense of $46 and $0 for the three months ended June 30, 2024 and 2023, respectively. Additionally, income tax expense for the six months ended June 30, 2024 and 2023 was of $62 and $0, respectively.The Company's effective tax rate for the three and six months ended June 30, 2024 and June 30, 2023 was 0.2% and 0%. The Company’s effective tax rates differ from the U.S. federal statutory rate of 21% for the three and six months end June 30, 2024 and June 30, 2023, respectively, primarily due to the valuation allowance. The effective tax rate for the three and six months ended June 30, 2024 is consistent with the three and six months ended June 30, 2023, as the Company has been in a full valuation allowance for both periods.

13. RELATED PARTY TRANSACTIONS

Effective November 2020, the Company issued a secured promissory note, where $1,000 was loaned to one of the Company's founders. The note receivable was secured by equity instruments with certain founders of the Company, bore interest at 3.25% per annum, and required the unpaid principal and unpaid interest balances to be paid on or before the maturity date of November 13, 2021. Effective December 28, 2023, the Company entered into a second amendment of the promissory note to extend the maturity date until November 13, 2024. According to the terms of the agreement, no additional interest will accrue through the payment date. The note has been fully reserved for as of December 31, 2023.

On March 2, 2021, the Company entered into the SBH Purchase Option with Stanley Brothers USA as discussed above (Note 3 "Fair Value Measurement"). The SBH Purchase Option was purchased for total consideration of $8,000. Certain founders of the Company, who are or were employees at the time, are the majority shareholders of Stanley Brothers USA.

On April 6, 2023, the Company jointly formed an entity, DeFloria, with AJNA and BAT. AJNA is a botanical drug development company. AJNA is partially owned and was co-founded by a co-founder of Charlotte's Web. BAT holds an equity interest in the entity in the form of 200,000 preferred units following its initial $10 million investment and has the right to participate in future equity issuances to maintain its pro rata equity position. The Company and AJNA each hold 400,000 of the entity's voting common units (Note 3). Effective May 1, 2023, the Company entered into an 8% interest bearing note receivable with DeFloria for the sale of lab equipment in the amount of $170. The principal and interest of the note receivable will be paid in 36 monthly installments. As of June 30, 2024, the remaining note receivable of $99, is presented in other assets in the condensed consolidated balance sheets. In 2024, BAT and AJNA invested an additional $5 million and $2 million, respectively, in DeFloria in the form of convertible debt (refer to Note 3). Additionally, on February 12, 2024, the Company and DeFloria entered into a separate master services agreement pursuant to which the Company will be compensated for the provision of certain services to DeFloria. For the three and six months ended June 30, 2024, the Company recognized $74 and $385 in revenue and cost of goods sold, respectively, related to the service agreement with DeFloria. Additionally, the Company has an accounts receivable balance due from DeFloria of $74, for the three and six months ended June 30, 2024, respectively.

On June 21, 2024, the Company entered into a consulting agreement with Jared Stanley, Co-Founder of Charlotte's Web, former executive of the Company, and current member of the Board of Directors. The consulting agreement will remain in effect until June 13, 2025. In consideration for Mr. Stanley's services, he will receive a bi-weekly fee of $6.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward Looking Statements

This Quarterly Report on Form 10-Q ("Form 10-Q") contains statements that are, or may be considered to be, "forward-looking statements" under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions. All statements other than statements of historical fact included in this Form 10-Q regarding the prospects of Charlotte's Web Holdings, Inc., ("Charlotte's Web", the "Company" or "we"), the industry or its prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as "plans," "expects" or "does not expect," "is expected," "look forward to," "budget," "scheduled," "estimates," "forecasts," "will continue," "intends," "the intent of," "have the potential," "anticipates," "does not anticipate," "believes," "should," "should not," or variations of such words and phrases that indicate that certain actions, events or results "may," "could," "would," "might," or "will," "be taken," "occur," or "be achieved," or the negative of these terms or variations of them or similar terms. Furthermore, forward-looking statements may be included in various filings that the Company makes with the SEC, on SEDAR +, or in press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. All capitalized and undefined terms used in this section shall have the same meanings hereafter defined in this Quarterly Report on Form 10-Q.

The following discussion and analysis of financial condition and results of operations should be read in conjunction with, and is qualified in its entirety by, the unaudited condensed consolidated financial statements and the accompanying notes in this Form 10-Q and the sections entitled "Item 1A. Risk Factors" and "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023. Except for historical information, the discussion in this section contains forward-looking statements that involve risks and uncertainties, as discussed in the "Cautionary Note Regarding Forward Looking Statements." Future results could differ materially from those discussed below for many reasons, including the risks described in Item 1A—"Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023.

Management's Discussion & Analysis of Charlotte's Web Holdings, Inc.

For purposes of this discussion, "Charlotte's Web," "CW," "we," "our", "us", or the "Company" refers to Charlotte's Web Holdings, Inc. and its subsidiaries: Charlotte's Web, Inc. and Abacus Products, Inc., and its wholly-owned subsidiaries: Abacus Health Products, Inc., Abacus Wellness, Inc. and CBD Pharmaceuticals Ltd. The results herein have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

Amounts are presented in thousands of United States dollars, unless otherwise indicated.

BUSINESS OVERVIEW

Charlotte's Web Holdings, Inc., is a Certified B Corp headquartered in Louisville, Colorado, which conducts the majority of its business in the United States. The Company is a market leader in innovative hemp extract wellness products under a family of brands which includes Charlotte's Web™, CBD Medic™, and CBD Clinic™. Charlotte's Web premium quality products start with proprietary hemp genetics that are 100% North American farm grown and are then manufactured into hemp extracts containing naturally occurring phytocannabinoids including CBD, cannabichromene ("CBC"), cannabigerol ("CBG"), terpenes, flavonoids and other cannabinoids and beneficial hemp compounds. The Company is headquartered in a cGMP compliant facility in Louisville, Colorado, where the Company conducts its production of tinctures, distribution, and quality control activities, as well as research and development ("R&D"). Charlotte's Web product categories include full spectrum hemp extract oil tinctures (liquid products), gummies, capsules, CBD topical creams and lotions, and pet products. The Company also offers NSF Certified for Sports® broad spectrum tincture and gummy products. Charlotte's Web products are distributed to retailers and health care practitioners, and online through the Company's website at www.CharlottesWeb.com. The information provided on the website is not part of this MD&A.

The Company's business consists of the farming, manufacturing, marketing, and sales of hemp-derived CBD wellness products. As of June 30, 2024, the Company operated in a single operating and reportable segment, hemp-derived CBD wellness products. The executive officers reviewed overall operating results in order to assess financial performance and to make resource allocation decisions, rather than to assess a lower-level unit of operations in isolation.

The Company's primary products are made from proprietary strains of whole-plant hemp extracts containing a full spectrum of phytocannabinoids, terpenes, flavonoids and other hemp compounds. The Company believes the presence of these various compounds work synergistically to heighten the effects of the products, making them superior to single-compound isolates.

Hemp extracts are produced from Cannabis and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a THC concentration of not more than 0.3% on a dry weight basis. The Company is engaged in research involving a broad variety of compounds derived from Hemp. Where research provides evidence that a greater than 0.3% THC level may have a potential therapeutic use, the Company may consider pursuing development of that use in jurisdictions where it is legal to do so in accordance with applicable regulations and if consistent with the Company's founding principles. The Company does not currently have any plans to expand into high THC products in the near future.

Recent Developments

With an increased commitment to innovation, Charlotte's Web has refreshed its mission to "Unearth the Science of Nature to Revolutionize Wellness," and is evolving its wellness offerings both to strengthen our core leadership in CBD, and extend beyond CBD to include a broader range of botanical wellness solutions, including minor cannabinoids. A testament to this expansion is the launch of Charlotte's Web Stay Asleep Cannabinol ("CBN") gummies. Similar to Cannabidiol ("CBD"), CBN is a non-intoxicating cannabinoid found in the hemp plant. At the cutting edge of innovative natural sleep solutions, these new melatonin free gummies could offer distinct benefits for the approximately 67% of adults who report waking up during the night (Phillips Global Sleep Survey, 2019). This is the first CBN sleep product supported by placebo-controlled peer-reviewed research study, offering a 20 mg dose of CBN. The Stay Asleep gummy demonstrates Charlotte's Web's commitment to science-backed products, providing an effective alternative to more traditional sleep supplements and medications. Charlotte's Web believes expanding beyond CBD leverages the Company's brand recognition, intellectual property, and partnerships, including an ongoing collaboration with DeFloria LLC ("DeFloria") for botanical drug development.

During the first quarter of 2024, Charlotte's Web unveiled a significant competitive price reduction of its leading CBD oils, without sacrificing its proprietary formulation or quality. This was accomplished by passing through improved operational efficiencies to consumers, with modest gross margin reduction expected to be offset with additional volume through the remainder of the year. More affordable pricing improves consumer accessibility, and broadens the total addressable consumer segments, attracting new consumers.

To better leverage its leading brand equity, the Company consolidated its CBD Medic and CBD Clinic brands under a unified Charlotte’s Web brand architecture. Additionally, the Company's ReCreate brand has been absorbed under the recognized Charlotte’s Web brand to better penetrate the lifestyles category. Charlotte’s Web NSF Certified for Sport® will benefit from the Company’s valuable professional sports partnerships, including the Angel City Football Club, U.S. Premier Lacrosse League, and Major League Baseball©.

As of June 30, 2024, several states have adopted new regulations that will impact the Company's ability to sell certain products as currently formulated or packaged in these states. Many of these states have also implemented new THC/CBD limits, age verification, labeling and packaging requirements. The Company continues to assess the business and financial impacts of the new regulations, including steps that can be taken to address the new product formulation,packaging, and labeling requirements, as well as costs and potential revenue impacts and anticipated timing for such impacts to the Company in these states.

The Company continues to invest in R&D efforts to identify new product opportunities. The Company is working to capitalize on the rapidly emerging botanical wellness products industry by driving customer acquisition and retention, as well as accelerating retail expansion. In addition, the Company may consider expanding its product line beyond Hemp-based products should the science and the Company's founding principles support such expansion.

Selected Financial Information


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2024		2023		2024		2023
Total revenues	$	12,289	$	16,006	$	24,413	$	33,016
Cost of goods sold	9,707		7,088		14,920		14,181
Gross profit	2,582		8,918		9,493		18,835
Selling, general, and administrative expenses	14,727		19,627		30,007		37,140
Operating loss	(12,145)		(10,709)		(20,514)		(18,305)
Gain on initial investment in unconsolidated entity	—		10,700		—		10,700
Change in fair value of financial instruments	1,140		4,229		(720)		9,612
Other income (expense), net	(6)		(1,376)		605		(2,074)
Income (loss) before income taxes	$	(11,011)	$	2,844	$	(20,629)	$	(67)
Total assets					$	129,794	$	176,589
Total liabilities					$	93,966	$	98,228

For The Three Months Ended June 30, 2024 and 2023

Revenue

The majority of the Company’s revenue is derived from sales of branded products to consumers via the Company’s DTC e-commerce website, and distributors, retail and wholesale B2B customers.


	Three Months Ended June 30,				% Increase (Decrease)
	2024		2023
Direct-to-consumer ("DTC") revenue	$	7,820	$	10,734	(27.1)	%
Business-to-business ("B2B") revenue	4,395		5,272		(16.6)	%
Service revenue	74		—		100.0	%
Total revenue	$	12,289	$	16,006	(23.2)	%

Total revenue for the three months ended June 30, 2024 was $12,289, a decrease of 23.2% compared to the three months ended June 30, 2023.

DTC net revenue decreased 27.1% year-over-year, primarily due to lower comparable online traffic to the Company’s web store. On a quarter-over-quarter basis DTC net revenue increased 0.6% compared to the first quarter of 2024. In June 2024, the Company transitioned to a new e-commerce platform which provides improved software integrations, advanced target marketing tools, and superior customer relationship management software.

B2B net revenue decreased 16.6% year-over-year, primarily due to reductions or removals of shelf space allocations to CBD products by certain retailers. Inflationary impact on discretionary consumer spending activity and product mix shift away from higher-priced tinctures were additional contributing factors. B2B net revenue increased 8.8% quarter-over-quarter compared to the first quarter of 2024. During the second quarter of 2024, Charlotte’s Web rolled out its new CBN 'Stay Asleep' gummies to retailers. The Company also added Walmart as a retail partner with the launch of a new CBD isolate topicals, now available at 827 Walmart stores across five states; California, Illinois, Florida, Texas, and Pennsylvania.

Cost of Goods Sold

Cost of goods sold includes the cost of inventory sold, changes in inventory provisions, and other production costs expensed. Other production costs include direct and indirect production costs including direct labor, processing, testing, packaging, quality assurance, security, shipping, depreciation of production equipment, indirect labor, including production management, and other related expenses. The primary factors that can impact cost of goods sold on a period-to-period basis include the volume of products sold, mix of product sold, third-party quality costs, transportation, overhead allocations and changes in inventory provisions.

The components of cost of goods sold are as follows:


	Three Months Ended June 30,				% Increase (Decrease)
	2024		2023
Inventory expensed to cost of goods sold	4,316		4,979		(13.3)	%
Inventory provision, net	3,830		127		2915.7	%
Other production costs	638		1,085		(41.2)	%
Service costs	74		—		100.0	%
Depreciation and amortization	849		897		(5.4)	%
Cost of goods sold	$	9,707	$	7,088	36.9	%

Cost of goods sold increased 36.9% for the three months ended June 30, 2024 compared to the three months ended June 30, 2023. The increase was primarily due to a $3.7 million increase in inventory provisions during the period. The increase in the provision was due to the revaluation on aged hemp based on current market conditions. The decrease was partially offset by lower inventory expense associated with lower revenue in 2024, as well as production cost improvements.

Depreciation and amortization expense for the three months ended June 30, 2024 and June 30, 2023 was $2,489 and $3,977, respectively, of which $849 and $897, respectively, was expensed to cost of goods sold. The remaining depreciation and amortization expenses of $1,640 and $3,080, respectively, was expensed to Selling, general, and administrative expenses.

Gross Profit

The primary factors that can impact gross profit margins include the volume of products sold, revenue mix between DTC e-commerce and B2B, product sales mix, promotional and sales discount rate, manufacturing spend, transportation costs, and changes in inventory provisions.

Gross profit for the three months ended June 30, 2024 and June 30, 2023 is as follows:


	Three Months Ended June 30,						% Increase (Decrease)
	2024			2023
Gross profit	$	2,582		$	8,918		(71.0)	%
Gross margin	21.0		%	55.7		%	(62.3)	%

Gross profit decreased 71.0% for the three months ended June 30, 2024 compared to the three months ended June 30, 2023. The decrease is primarily related to the increase in inventory provision of $3.7 million for the three month ending June 30, 2024. Additionally the decrease is directly related to the revenue decrease of 23.2%, primarily due to lower blended margin following price reductions on oil tincture products initiated in the first quarter of 2024.

Selling, General, and Administrative Expenses

Total Selling, general, and administrative expenses are as follows:


	Three Months Ended June 30,				% Increase (Decrease)
	2024		2023
Selling, general, and administrative expenses	$	14,727	$	19,627	(25.0)	%

Total Selling, general, and administrative expenses for the three months ended June 30, 2024 and June 30, 2023 were $14,727 and $19,627, respectively. The amended MLB Promotional Rights Agreement resulted in a decrease in amortization expense related to MLB assets of approximately $1 million compared to the three months ended June 30, 2023. Additionally, the decrease is due to a reduction in personnel, share based compensation, and consulting costs compared to the prior period.

Depreciation and amortization expensed to Selling, general, and administrative expenses for the three months ended June 30, 2024 and June 30, 2023 were $1,640 and $3,080, respectively.

Total research and development costs expensed to Selling, general, and administrative expense for the three months ended June 30, 2024 and June 30, 2023 were $648 and $916, respectively. Research and development expenses primarily include personnel costs related to our R&D science division as well as R&D related projects advancing Hemp cannabinoid science through research programs that provide a better understanding of the possible therapeutic uses of cannabinoids.

Total Change in Gain on Investment in Unconsolidated Entity

Total change in gain on investment in unconsolidated entity is as follows:


	Three Months Ended June 30,				% Increase (Decrease)
	2024		2023
Change in gain on investment in unconsolidated entity	$	—	$	10,700	(100)	%

The gain on investment in unconsolidated entity for the three months ended June 30, 2024 and June 30, 2023 was $0 and $10,700, respectively. For the six months ended June 30, 2023, the gain was due to the Company jointly forming an entity, DeFloria, with AJNA, and BAT. DeFloria was established to pursue FDA approval for a novel botanical drug to target a neurological condition, with the botanical drug being developed from certain proprietary hemp genetics of the Company. The initial investment was measured at fair value and is remeasured at each reporting date, with changes recognized in changes in fair value of financial instruments.

Total Change in Fair Value of Financial Instruments

Total change in fair value of financial instruments is as follows:


	Three Months Ended June 30,				% Increase (Decrease)
	2024		2023
Change in fair value of financial instruments	$	1,140	$	4,229	(73.0)	%

Total change in fair value of financial instruments for the three months ended June 30, 2024 and June 30, 2023 was $1,140 and $4,229, respectively. For the three months ended June 30, 2024, the gain in fair value of financial instruments was primarily due to the revaluation of the fair value of the investment in unconsolidated entity, resulting in a gain of $1 million, compared to no gain for the three months ended June 30, 2023.

For the three months ended June 30, 2023, the gain in fair value of financial instruments was due to the Company's debt conversion option and debt interest rate conversion feature resulting in a net gain of approximately $4.2 million, compared to a net gain of $175 for the three

months ended June 30, 2024. The fair value of the Company's embedded derivatives and options are revalued at each reporting date with changes impacted by variability in the Company's share price and implied debt yields.

For the Six Months Ended June 30, 2024 and 2023

Revenue

The majority of the Company’s revenue is derived from sales of branded products to consumers via the Company’s DTC e-commerce website, and distributors, retail and wholesale B2B customers.


	Six Months Ended June 30,				% Increase (Decrease)
	2024		2023
Direct-to-consumer ("DTC") revenue	$	15,592	$	22,002	(29.1)	%
Business-to-business ("B2B") revenue	8,436		11,014		(23.4)	%
Service revenue	385		$	—	100.0	%
Total revenue	$	24,413	$	33,016	(26.1)	%

Total revenue for the six months ended June 30, 2024 was $24,413, a decrease of 26.1% compared to the six months ended June 30, 2023.

DTC revenue decreased 29.1%, driven by lower comparable online traffic and associated sales volume through the Company’s web store. Inflationary impact on discretionary consumer spending activity and product mix shift away from higher-priced tinctures were additional contributing factors.

B2B revenue decreased 23.4% compared to the six months ended June 30, 2023. The decrease was primarily due to the reduced retailer shelf allocations to the CBD category and inflationary impacts on consumer spending.

Cost of Goods Sold

The components of cost of goods sold are as follows:


	Six Months Ended June 30,				% Increase (Decrease)
	2024		2023
Inventory expensed to cost of goods sold	7,698		10,188		(24.4)	%
Inventory provision, net	3,926		320		1126.9	%
Other production costs	1,206		1,877		(35.7)	%
Service costs	385		—		100.0	%
Depreciation and amortization	1,705		1,796		(5.1)	%
Cost of goods sold	$	14,920	$	14,181	5.2	%

Cost of goods sold increased 5.2% for the six months ended June 30, 2024, despite lower revenue compared to the six months ended June 30, 2023. The increase was primarily due to a $3.7 million increase in inventory provisions taken as of June 30, 2024. The increase in the provision was due to the revaluation on aged hemp based on current market conditions. The increase was partially offset by lower inventory expense associated with lower revenue in 2024, as well as production cost improvements.

Depreciation and amortization expense for the six months ended June 30, 2024 and June 30, 2023 was $4,982 and $7,769, respectively, of which $1,705 and $1,796, respectively, was expensed to cost of goods sold. The remaining depreciation and amortization expenses of $3,277 and $5,973, respectively, was expensed to Selling, general, and administrative expenses.

Gross Profit

The primary factors that can impact gross profit margins include the volume of products sold, the mix of revenue between DTC e-commerce and B2B, the mix of products sold, the promotional and sales discount rate, third-party quality costs, transportation costs, and changes in inventory provisions.

Gross profit for the six months ended June 30, 2024 and June 30, 2023 is as follows:


	Six Months Ended June 30,						% Increase (Decrease)
	2024			2023
Gross profit	$	9,493		$	18,835		(49.6)	%
Gross margin	38.9		%	57.0		%	(31.8)	%

Gross profit decreased 49.6% year-over-year for the six months ended June 30, 2024 primarily due to the lower net revenue and higher inventory provisions compared to the same period ended June 30, 2023.

Selling, General, and Administrative Expenses

Total Selling, general, and administrative expenses are as follows:


	Six Months Ended June 30,				% Increase (Decrease)
	2024		2023
Selling, general, and administrative expenses	$	30,007	$	37,140	(19.2)	%

Total selling, general, and administrative expenses for the six months ended June 30, 2024 and June 30, 2023 were $30,007 and $37,140, respectively. The amended MLB Promotional Rights Agreement resulted in a decrease in amortization expense related to MLB assets of approximately $2 million compared the prior period. Additionally, the decrease is due to a reduction in personnel and consulting costs compared to the prior period.

Depreciation and amortization expensed to Selling, general, and administrative expenses for the six months ended June 30, 2024 and June 30, 2023 were $3,277 and $5,973, respectively.

Total research and development costs expensed to Selling, general, and administrative expense for the six months ended June 30, 2024 and June 30, 2023 were $1,399 and $1,462, respectively. Research and development expenses primarily include personnel costs related to the Company's R&D science division as well as R&D related projects advancing Hemp cannabinoid science through research programs that provide a better understanding of the possible therapeutic uses of cannabinoids.

Total Change in Gain on Investment in Unconsolidated Entity

Total change in gain on investment in unconsolidated entity is as follows:


	Six Months Ended June 30,				% Increase (Decrease)
	2024		2023
Change in gain on investment in unconsolidated entity	$	—	$	10,700	(100)	%

Total change in gain on investment in unconsolidated entity for the six months ended June 30, 2024 and June 30, 2023 was $0 and $10,700, respectively. For the six months ended June 30, 2023, the gain was due to the Company jointly forming an entity, DeFloria, with

AJNA, and BAT. DeFloria was established to pursue FDA approval for a novel botanical drug to target a neurological condition, with the botanical drug being developed from certain proprietary hemp genetics of the Company. The initial investment was measured at fair value and is remeasured at each reporting date, with changes recognized in changes in fair value of financial instruments.

Total Change in Fair Value of Financial Instruments

Total change in fair value of financial instruments is as follows:


	Six Months Ended June 30,				% Increase (Decrease)
	2024		2023
Change in fair value of financial instruments	$	(720)	$	9,612	(107)	%

Total change in fair value of financial instruments for the six months ended June 30, 2024 and June 30, 2023 was a loss of $720 and a gain of $9,612, respectively. For the six months ended June 30, 2024, the loss in fair value of financial instruments was primarily due to the revaluation of the fair value of the Company's SBH purchase option resulting in a loss of $1 million, compared to a loss of $243 for the six months ended June 30, 2023. The decrease in valuation resulted from declining financial projections of SBH.

For the six month ending June 30, 2023, the gain in fair value of financial instruments was due to the revaluation of the fair value of the Company's debt conversion option and debt interest rate conversion feature resulting in a net gain of approximately $9.6 million, compared to a net gain of $65 for the six months ended June 30, 2023. The fair value of the Company's embedded derivatives and options are revalued at each reporting date, with changes impacted by variability in the Company's share price and implied debt yields.

Liquidity and Capital Resources

As of June 30, 2024 and December 31, 2023, the Company had total current liabilities of $18,467 and $23,646, respectively, and cash and cash equivalents of $32,531 and $47,820, respectively, to meet its current obligations.

As a result of expense reduction actions taken in 2024, the Company expects selling, general and administrative expenses to be significantly lower compared to 2023.

The Company’s ability to fund its operations for the next twelve months and thereafter will depend on its future operating performance, particularly prudent cost management, which can be affected by general economic conditions, industry regulatory changes, and other factors beyond the Company’s control.

Management continually assesses liquidity in terms of the ability to generate sufficient cash flow to fund the business. Net cash flow is affected by the following items: (i) operating activities, including the cash impacts from the statements of operations, the level of accounts receivables, accounts payable, accrued liabilities and unearned revenue and deposits; (ii) investing activities, including the purchase of property and equipment; and (iii) financing activities, including the issuance of capital shares.

The Company expects to meet our liquidity requirements for at least the next twelve months through various sources of capital, including cash on hand and provided by operations over time. The Company regularly considers fundraising opportunities and may decide, from time to time, to raise capital through borrowings or issuances of additional equity and/or debt securities. The Company's ability to incur additional debt is dependent upon a number of factors, including the state of the credit markets, our degree of leverage, the value of our unencumbered assets and borrowing restrictions imposed by lenders, including restrictions on the industry. The Company's ability to raise funds through the issuance of additional equity and/or debt securities is also dependent on a number of factors including the current state of the capital markets, investor sentiment and intended use of proceeds. The Company's ability to raise funds through the issuance of equity securities depends on, among other things, general market conditions for companies in the Hemp industry and market perceptions about us. There can be no assurance the Company will have the ability to raise additional funds and, if raised privately or publicly, will be available to the Company when needed or on terms which are acceptable.

Cash Flows

Cash from Operating Activities

Net cash used in operating activities for the six months ended June 30, 2024 and June 30, 2023 were as follows:


	Six Months Ended June 30,
	2024		2023
Net cash used in operating activities	$	(11,883)	$	(5,009)

For the six months ended June 30, 2024, the decrease in cash used in operations is primarily due to a decrease in sales and working capital, resulting in a decrease of net cash inflow. Additionally, for the six months ended June 30, 2023, the Company collected $4,261 from income tax refunds due.

Cash from Investing Activities

Net cash used in investing activities for the six months ended June 30, 2024 and June 30, 2023 were as follows:


	Six Months Ended June 30,
	2024		2023
Net cash used in investing activities	$	(3,288)	$	(151)

For the six months ended June 30, 2024, the increase in cash used in investing activities was driven primarily by machinery purchases as part of the Company's plan to in-source topical and gummy production..

Cash from Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2024 and June 30, 2023 were as follows:


	Six Months Ended June 30,
	2024		2023
Net cash used in financing activities	$	(118)	$	(75)

For the six months ended June 30, 2024, the change was primarily due to the vesting of restricted stock units.

Off-Balance Sheet Arrangements

As of June 30, 2024 and December 31, 2023, we do not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on our results of operations or financial condition, including, and without limitation, such considerations as liquidity and capital resources.

Related party transactions

On April 6, 2023, the Company jointly formed an entity, DeFloria, with AJNA and BAT. AJNA is a botanical drug development company. AJNA is partially owned and was co-founded by a co-founder of Charlotte's Web. BAT holds an equity interest in the entity in the form of 200,000 preferred units following its $10 million initial investment and has the right to participate in future equity issuances to maintain its pro rata equity position. The Company and AJNA each hold 400,000 of the entity's voting common units (Note 3). Effective May 1, 2023, the Company entered into an 8% interest bearing note receivable with DeFloria for the sale of lab equipment in the amount of $170. The principal and interest of the note receivable will be paid in 36 monthly installments. As of June 30, 2024, the remaining note receivable of $99, is presented in other assets in the condensed consolidated balance sheets. In 2024, BAT and AJNA invested an additional $5 million and $2 million, respectively, in DeFloria in the form of convertible debt (refer to Note 3). Additionally, on February 12, 2024, the Company and DeFloria entered into a separate master services agreement pursuant to which the Company will be compensated for the provision of certain services to DeFloria. For the three and six months ended June 30, 2024, the Company recognized $74 and $385, respectively, in revenue and cost of goods sold, respectively, related to the service agreement with DeFloria. Additionally, the Company has an accounts receivable balance due from DeFloria of $74, respectively, for the three and six months ended June 30, 2024.

Recently Adopted Accounting Principles

Critical Policies and Accounting Estimates

Listed below are the accounting policies and estimates we believe are critical to our financial statements due to the degree of uncertainty regarding the estimates or assumptions involved and the magnitude of the asset, liability, revenue or expense being reported. Please also refer to Note 2 of our notes to condensed consolidated financial statements for a discussion on recently adopted and issued accounting pronouncements.

Fair Value Option

The Company has elected the fair value option in accordance with ASC 825-10 guidance to record its SBH Purchase Option. Under ASC 825-10, a business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date. The SBH Purchase Option is classified as a financial asset in the condensed consolidated balance sheets and is remeasured at fair value at each reporting date, with changes to fair value recognized in the condensed consolidated statements of operations for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. The Monte Carlo valuation model considers multiple revenue and EBITDA outcomes for Stanley Brothers USA and other probabilities in assigning a fair value. Primary assumptions utilized include financial projections of Stanley Brothers USA and the probability and timing of exercise asserted by the Company.

Investment in Unconsolidated Entities

The Company has a variable interest in the investment in DeFloria; however, the Company is not the primary beneficiary of DeFloria as it lacks the power to direct DeFloria's key activities. The Company concluded that the investment in DeFloria should not be consolidated. In accordance with ASC 825-10, equity method investments are eligible for the fair value option as they represent recognized financial assets. As the Company was not required to consolidate the investment and does not meet any of the other scope exceptions, the Company had the ability to adopt the fair value option for the investment at inception. The investment was remeasured at fair value after each reporting date,

with changes recognized in condensed consolidated statements of operations, as changes in fair value of financial instruments for the period.

The use of assumptions for the fair value determination of the investment in Defloria included a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. To determine the value of the investment, the Company utilizes an Option Pricing Model (OPM). The OPM considers the various terms of the stockholder agreements, including the level of seniority among the securities, dividend policy, conversion ratios, and cash allocations upon liquidation of the entity. The OPM is appropriate when the range of potential future outcomes is difficult to predict with any certainty.

Inventories

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less any applicable selling expenses. Cost includes all expenses for direct raw materials inputs, as well as costs directly attributable to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity. Cost is determined by use of the weighted average method. To determine if a provision for inventories is required, the Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions, including forecasted demand compared to quantities on hand, as well as other factors such as potential excess or aged inventories based on product shelf life, and other factors that affect inventory obsolescence. The Company's inventories of harvested hemp are recorded at cost to grow and harvest. Raw materials costs as well as production costs are included in the carrying value of the Company's finished goods inventory. The Company's inventory production process for cannabinoid products includes cultivating of botanical raw material. Because of the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset.

Impairment of Long-Lived Assets

The Company reviews intangible assets with indefinite useful lives for impairment at least annually and reviews all intangible assets for impairment whenever events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. Long-lived assets, such as property and equipment and intangible assets subject to depreciation and amortization, as well as indefinite lived intangibles and goodwill are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable or that the useful life is shorter than the Company had originally estimated. Recoverability of these assets is measured by comparison of the carrying amount of each asset or asset group to the future undiscounted cash flows the asset or asset group is expected to generate over their remaining lives. If the asset or asset group is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset or asset group. If the useful life is shorter than originally estimated, the Company amortizes the remaining carrying value over the new shorter useful life. Impairment losses are recorded in selling, general, and administrative expense in the condensed consolidated statements of operations. There were no impairment losses recognized for the three months ended June 30, 2024 and 2023, respectively.

Convertible Debenture

The Company determined that the debenture is a freestanding financial instrument, which includes embedded derivatives. The embedded derivatives have been bifurcated from the debenture and accounted for separately in accordance with the provisions of ASC 815, Derivatives and Hedging. The Company reviewed the terms of the debenture and identified two material embedded features which required bifurcation and separate accounting pursuant to the provisions of ASC 815: 1) the interest rate conversion feature based on changes in federal regulations, and 2) the debt conversion option to common shares. The debt interest rate conversion feature is classified as a derivative asset and measured at fair value using a probability weighted income approach. The debt conversion option is classified as a derivative liability and measured at fair value using a Black-Scholes option pricing model. The Company allocated proceeds first to the derivatives measured at fair value and the residual amount was allocated to the debenture. Debt issuance costs are allocated to the debenture. The debt issuance costs are presented as a direct reduction from the face value of the debenture and amortized over the stated term of the debenture.

Income Taxes

The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets or liabilities are computed based on the temporary difference between the financial statement and income tax basis of assets and liabilities

using the enacted marginal income tax rate in effect for the year in which the differences are expected to reverse. Deferred income tax expense or benefit is based on the changes in the deferred income tax assets or liabilities from period to period. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized.

Significant judgment is required in determining the Company's provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. The Company assesses the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income or loss, earnings history, and forecasting reliability. It is the Company's policy to offset indefinite lived deferred tax assets with indefinite lived deferred tax liabilities. The Company provided a full valuation allowance on deferred tax assets because it is more likely than not that deferred tax assets will not be realized.

The Company accounts for uncertainties in income taxes under ASC Topic 740, which prescribes a recognition threshold and measurement methodology to recognize and measure an income tax position taken, or expected to be taken, in a tax return. With respect to any tax positions that do not meet the recognition threshold, a corresponding liability, including interest and penalties, is recorded in the condensed consolidated financial statements. The Company may be subject to examination by tax authorities where the Company conducts operations. The earliest income tax year that may be subject to examination is 2019. The Company has recorded an uncertain tax position as of June 30, 2024 and December 31, 2023. The Company's policy is to recognize interest and penalties on taxes, if any, within the condensed consolidated statement of operations as income tax expense.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customer ("ASC 606"). The Company elected to early adopt ASC 606 as of January 1, 2018, as permitted by the standard. The Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to arrangements that meet the definition of a contract under the standard, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of revenue accounting, the Company evaluates the goods or services promised within each contract related performance obligation and assesses whether each promised good or service is distinct. The Company recognizes as revenue, the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company recognizes revenue from customers when control of the goods or services are transferred to the customer, generally when products are shipped, at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Freight revenue is included in revenue on the condensed consolidated statements of operations, and is generally exempt from state sales taxes. Sales tax collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from revenue in the condensed consolidated statements of operations. Contracts are written to include standard discounts and allowances. Contracts are not written to include advertising allowances, tiered discounts or any other performance obligation. Since the Company's contracts involve the delivery of various tangible products, the arrangements are considered to contain only a single performance obligation, as such there is no allocation of the transaction price. The Company also offers e-commerce discounts and promotions through its online rewards program. The Charlotte's Web Loyalty Program offers customers rewards points for every dollar spent through the Company website to earn store credit for future purchases. The Company defers recognition of revenue for unredeemed awards until the following occurs: (1) rewards are redeemed by the consumer, (2) points or certificates expire, or (3) an estimate of the expected unused portion of points or certificates is applied, which is based on historical redemption patterns.

Any product that does not meet the customer's expectations can be returned within the first 30 days of delivery in exchange for another product or for a full refund. Generally, any product sold through a distributor or retailer must be returned to the original purchase location for any return or exchange. The Company accounts for customer returns utilizing the "expected value method." Expected amounts are excluded from revenue and recorded as a "refund liability" that represents the Company's obligation to return the customer’s consideration. Estimates are based on actual historical and current specific data.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The information under this item is not required to be provided by smaller reporting companies.

Item 4. Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of June 30, 2024, our disclosure controls and procedures were effective to ensure the timely disclosure of required information in our SEC filings.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ending June 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II

Item 1. Legal Proceedings

From time to time, the Company may be involved in various regulatory issues, claims and lawsuits arising in the ordinary course of business, none of which, in the opinion of management, is expected to have a material adverse effect on the Company’s results of operations or financial condition.

At present, the Company is not a party to any material pending legal proceedings, other than ordinary routine litigation incidental to the business. Nor is the Company or its property the subject of any legal proceedings, known or contemplated, that involve a claim for damages exclusive of interest and costs that meet or exceed 10% of its current assets.

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the year ended December 31, 2023 includes a detailed discussion of our risk factors under the heading "Part I, Item 1A—Risk Factors." There have been no material changes from such risk factors during the quarter ended June 30, 2024. You should consider carefully the risk factors set forth in this Form 10-Q and discussed in our Annual Report on Form 10-K for the year ended December 31, 2023 and all other information contained in or incorporated by reference in this Form 10-Q before making an investment decision. If any of the risks discussed herein or in the Annual Report on Form 10-K for the year ended December 31, 2023 actually occur, they may materially harm our business, financial condition, operating results, cash flows or growth prospects. As a result, the market price of our common shares could decline, and you could lose all or part of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial may also materially harm our business, financial condition, operating results, cash flows or growth prospects and could result in a complete loss of your investment.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During the three months ended June 30, 2024, none of the Company's directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).

Item 6. Exhibits

Documents filed as part of this report

Exhibit No.

Description

Location

10.1†

Offer Letter from Charlotte’s Web Holdings, Inc. to Erika Lind, dated June 17, 2024.

Exhibit 10.1 to the Current Report on Form 8-K (File No. 000-56364) filed with the SEC on June 20, 2024 is incorporated herein by reference.

10.2†

Consulting Agreement between Char lotte’s Web Holdings, Inc. and Jared Stanley, dated June 13, 2024 .

Filed herewith

31.1

Certification of Periodic Report by Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

Filed herewith

31.2

Certification of Periodic Report by Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

Filed herewith

32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Furnished herewith

32.2

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Furnished herewith

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

Filed herewith

101.SCH

Inline XBRL Taxonomy Extension Schema Document

Filed herewith

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

Filed herewith

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

Filed herewith

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

Filed herewith

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Filed herewith

†

Indicates a management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		CHARLOTTE'S WEB HOLDINGS, INC.

August 8, 2024	By:	/s/ Erika Lind
(Date)		Erika Lind
		(Chief Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

Signatures

Title

Date

/s/ William Morachnick

Chief Executive Officer (Principal Executive Officer)

August 8, 2024

William Morachnick

/s/ Erika Lind

Chief Financial Officer (Principal Financial Officer)

August 8, 2024

Erika Lind

/s/ Sarah Cambridge

Chief Accounting Officer (Principal Accounting Officer)

August 8, 2024

Sarah Cambridge

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (this “Agreement”) is entered into as of the date set forth on the signature page hereto (the “Effective Date”), by and between the individual or entity set forth on the signature page hereto (“Consultant”), and CHARLOTTE’S WEB, INC. (“Company”) (individually a “Party” or together the “Parties”). All capitalized terms not defined when initially used will have the meanings given to them elsewhere in this Agreement.

WHEREAS, (i) Company is a developer, marketer, distributor and seller of certain consumer products (the “Products”), (ii) Consultant wishes to provide the Services for Company, and (iii) Company wishes to procure the Services from Consultant, in exchange for the compensation set forth in Section 2 herein.

WHEREAS, Consultant is not an employee of the Company and has previously resigned as an employee of the Company.

NOW THEREFORE, in consideration of the foregoing premises, and the covenants and undertakings herein contained, Consultant and Company mutually agree as follows:

1.Services. Consultant will be responsible for the execution of the Services to the reasonable satisfaction of Company, and Consultant will coordinate any and all elements of the Services directly with Company and subject to Company’s approval. For purposes of this Agreement, “Services” will refer to (i) the services described on Exhibit A attached to this Agreement and (ii) such other related services as Company may reasonably request from time to time.

2.Compensation. In consideration of the Services to be provided by Consultant to Company hereunder, Company agrees to pay Consultant the following compensation:

(a)Fee. During the Term, Consultant will receive the monthly, weekly, hourly or other fee specified on Exhibit A attached hereto (the “Fee”).

(b)Expense Reimbursement. In addition to the Fee, Company will reimburse Consultant for its reasonable, out-of-pocket expenses directly related to the Services during the Term (the “Service Expenses”); provided that, any Service Expenses in excess of $600 (individually or in the aggregate) will not be reimbursed to Consultant unless authorized by Company in writing prior to Consultant incurring such Service Expenses (email authorization being sufficient). Consultant will provide Company with invoices for all Service Expenses.

3.Term; Termination. This Agreement will commence as of the Effective Date and remain in full force and effect until (a)June 13, 2025, or (b) terminated by either Party, at any time, for any or no reason, upon ten (10) days prior written notice to the other Party (the period from the Effective Date until such time as this Agreement is terminated will be referred to as the “Term”); provided, however, that Company will have the right to treat any termination of this Agreement by Consultant as effective immediately upon Company’s receipt of such written notice. In the event this Agreement is terminated pursuant to this Section 3, Company will have no further financial or other obligation to Consultant except for payment for Services rendered up to the effective date of such termination, subject to pro-ration, as applicable.

4.Intellectual Property.

(a)Consultant represents, warrants and covenants that Company will be the owner of all of the results and proceeds of Consultant’s Services under this Agreement, including any copyrights, patents, trademarks and other intellectual property rights in any work or property created by Consultant, or anyone under Consultant’s direction under this Agreement and any marketing, promotional, literary or other materials created in connection with the performance of the Services hereunder including, without limitation, any film, video, still photograph, digital recording, graphics, designs, artwork, models, prototypes, inventions, recipes, formulae, processes and writings (collectively, the “IP”). Consultant acknowledges that its work and the Services are a “work-made-for-hire” within the scope of Consultant’s Services to Company, and therefore Company will be the author and intellectual property owner of any work and any IP, created under this Agreement. Where, by operation of law, any of the rights described herein including, without limitation, any rights to the IP, do not vest initially in Company, good and valuable consideration being extant, the adequacy and receipt of which Consultant hereby acknowledges, Consultant irrevocably assigns and transfers to Company, in perpetuity, all of Consultant’s worldwide rights, title and interest, whether such rights are vested or contingent, in and to any such IP including, without limitation, any copyrights, patents, trademarks and other intellectual property rights, to Company. Consultant understands and agrees that it will not use the IP in any manner whatsoever, for any purpose whatsoever, except as necessary to provide the Services and it will not disseminate any such IP, in any manner, without the prior written consent of Company.

(b)Without limiting the generality of Section 4(a) above, Consultant further represents, warrants and covenants that: (i) all processes, know-how, methods, formulations and/or specifications created, developed and/or improved upon by either party in connection with the Services, including, without limitation, any development, formulation, sample and testing runs of Company’s products (collectively, as applicable, the “Product Tests”), which in any way pertain to the production or manufacture of any of Company’s existing or future products (including, without limitation, any products developed by Consultant for Company as a result of the Product Tests), shall be the sole and exclusive property of Company; (ii) Consultant shall not acquire any right, title or interest in or to Company’s specifications or Company’s products, or any intellectual property right relating thereto, as a result of its performance of Services on behalf of Company or otherwise (including, without limitation, any Product Tests); and (iii) Consultant shall not obtain any right to disclose or utilize any such product specifications or other information except as explicitly authorized by Company in writing. For the avoidance of doubt, any and all results of the Product Tests, together with all improvements thereon and modifications thereto, shall be deemed “IP” of Company.

5.Confidentiality. During the Term, Consultant acknowledges and agrees that Company may disclose to Consultant certain confidential information, which confidential information includes, but is not limited to, information pertaining to Company’s and its affiliates’ financial affairs, products, know-how, business systems, marketing strategies, trade secrets, manufacturing processes, production methods, recipes, formulae, designs, equipment, technology and other technical and commercial information, including, without limitation, information relating to the Product Tests (collectively, “Confidential Information”), solely to permit Consultant to perform its obligations under this Agreement. Consultant will maintain the secrecy of all such Confidential Information during the Term and thereafter. During the Term and thereafter,

Consultant will not use, disclose or otherwise exploit any Confidential Information for its own benefit, or for any purpose not specifically authorized by Company. All files, lists, records, documents and drawings that incorporate or refer to any Confidential Information will be returned to Company or destroyed promptly upon the termination of this Agreement.

6.Representations and Warranties; Company Property.

(a)Consultant represents and warrants that: (i) it has the full right, power, capacity and authority to enter into and fully perform this Agreement, and carry out each and all of the terms and conditions hereof; (ii) there is not now, nor will there exist during the Term, any contract or understanding with any other person or entity which would interfere with its performance of its obligations herein; (iii) the consent of no other person or entity is necessary for Consultant to enter into this Agreement; (iv) it will satisfy the terms and obligations of this Agreement in compliance with all applicable current or future federal, state, or local laws, statutes, orders, rules, regulations, ordinances, permits, approvals, licenses, registrations, directives, filings or authorizations; and (v) it will provide Company with prompt written notice of any legal or regulatory issues applicable to the execution of the Services of which Consultant is or later becomes aware.

(b)Consultant acknowledges and agrees that in the event Company provides Consultant with a lap top computer or other similar property, such property will at all times remain the property of Company and subject to Company’s review and inspection from time to time. Consultant further acknowledges and agrees that upon the cessation or termination of Consultant’s employment with Company, for any reason, Consultant will immediately return such property to Company.

7.Indemnification. Consultant will indemnify, hold harmless and defend Company, its parent, affiliate and subsidiary companies and their respective officers, directors, shareholders, agents and employees from and against any and all loss, liability, damage and expense (including reasonable attorneys’ fees and court costs) pertaining to, arising out of, in connection with or resulting from (i) Consultant’s gross negligence, recklessness or willful misconduct, and (ii) the breach by Consultant of any representation, warranty, covenant or obligation contained in this Agreement; provided, however, Consultant will have no indemnification obligation hereunder to the extent that any of the foregoing was caused by the acts or omissions of Company, or to the extent Consultant’s actions were taken at Company’s direction.

Company will indemnify, hold harmless and defend Consultant from and against any and all loss, liability, damage and expense (including reasonable attorneys’ fees and court costs) pertaining to, arising out of, in connection with or resulting from Consultant’s provisions of the Services as requested by the Company and actions taken at the Company’s direction; provided, however, Company will have no indemnification obligation hereunder to the extent that any of the foregoing are caused by (i) Consultant’s gross negligence, recklessness or willful misconduct, or (ii) the breach by Consultant of any representation, warranty, covenant or obligation contained in this Agreement.

8.Notices. All notices and other communications required or permitted under this Agreement will be in writing and will be delivered by (a) electronic mail, in which event the notice will be deemed effective when received, (b) hand, in which event the notice will be deemed effective when delivered, (c) prepaid registered or certified mail, return receipt requested, in which event

the notice will be deemed effective when received, or (d) recognized overnight courier services, in which event the notice will be deemed effective as of the regularly scheduled time for delivery established by such courier service. All notices and other communications under this Agreement will be given to the Parties hereto at the addresses set forth on the signature page to this Agreement. The Parties may designate that a notice be given to such other address as they may from time to time specify by written notice as herein provided to the other Party.

9.Independent Contractor. The Parties acknowledge and agree that: (i) Consultant is to perform the Services hereunder as an independent contractor; (ii) Company will not be liable for any federal, state, local, withholding or other taxes, worker's compensation, unemployment insurance, employers' liability, employer's FICA, social security or other deductions or contributions, for or on behalf of Consultant (or any other person retained or employed by Consultant); and (iii) all such related taxes and costs will be the sole responsibility of Consultant. Consultant is free to engage for employment or provision of services with other entities to the extent such engagement does not interfere with the provision of the Services hereunder.

10.Miscellaneous. Nothing in this Agreement will be construed as establishing the relationship of employer and employee, or principal and agent, or franchisor and franchisee, or of partnership, or of joint venture or of any similar association between the Parties. Neither Party will have the right to enter into any agreement that binds or obligates the other in any way, except as otherwise provided expressly in this Agreement. In the event any provision of this Agreement is determined to be invalid or unenforceable for any reason, such provision will be deemed modified, if possible, to the extent required to render it valid, enforceable and binding, and such determination will not affect the validity or enforceability of any other provision of this Agreement. The rights and obligations conferred hereunder cannot be assigned or delegated by either Party without the prior written consent of the other Party, and any purported assignment will be void; provided, however, that Company will have the right to assign this Agreement to a successor in interest in connection with a sale of all or substantially all of the assets and/or equity of Company without the prior written consent of Consultant. This Agreement may be executed in multiple counterparts, each such counterpart being deemed an original copy thereof. Failure by either Party at any time to enforce any of the terms hereof or a breach by the other Party will not constitute a waiver of any of the provisions hereof or of subsequent breaches. This Agreement constitutes the entire and final expression of the agreement between the Parties pertaining to the subject matter hereof, and supersedes all prior related communications or agreements, whether oral, written, or electronically transmitted, between the Parties. This Agreement may not be modified or amended without the written consent of the Parties. This Agreement will be governed by, and construed and enforced in accordance with, the laws of the State of Colorado, without regard to its conflict or choice of law principles. Notwithstanding the foregoing, the obligations set forth in the last sentence of Section 3, as well as the provisions of Sections 4, 5, 6, 7, 8, 9 and 10, will survive the termination of this Agreement.

[remainder of page intentionally left blank; signature page to follow]

IN WITNESS WHEREOF, the Parties have executed this Consulting Agreement as of the Effective Date set forth below.

Effective Date: June 13, 2024

ACCEPTED AND AGREED:

CONSULTANT:

Consultant Name:

Jared Stanley

__________________________________

Signature: /s/ Jared Stanley

If signing on behalf of an entity:

Signatory Title:

__________________________________

Notice: Address:

__________________________________

Email: ____________________________

COMPANY:

CHARLOTTE’S WEB, INC.

__/s/ Stephen Rogers_______

Name: Stephen Rogers

Title: General Counsel

Notice: Address:

__________________________________

Email: ____________________________

Exhibit A

Services

For purposes of this Agreement, the “Services” will include, but may not be limited to:

Consultation on government relations matters, including nationwide monitoring of federal and state legislation, efforts to educate lobbyists and lawmakers on the practicality of proposed legislation. In addition to services, Consultant may at times serve as a spokesperson as requested by the Company.

Consultation on cultivation as needed, including assistance with historical information, future planning needs, and expertise in the field. Continue completion of the Cultivation Roles and Responsibilities to provide clarity for the associated staff and external partner agencies.

Consultation on written communication, speaking engagements, and presentations on behalf of the Company as requested.

Fee

For purposes of this Agreement, the “Fee” will be:

$ 5,769.23 (USD) paid N14

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A‑14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002

I, William Morachnick, certify that:

1.I have reviewed this quarterly report on Form 10‑Q of Charlotte's Web Holdings, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2024


/s/ William Morachnick

William Morachnick

Chief Executive Officer

(Principal Executive Officer)

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13A‑14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002

I, Erika Lind, certify that:

1.I have reviewed this quarterly report on Form 10‑Q of Charlotte's Web Holdings, Inc.;

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2024


/s/ Erika Lind

Erika Lind

Chief Financial Officer

(Principal Financial Officer)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Charlotte's Web Holdings, Inc. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission (the "Report"), I, William Morachnick, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Dated: August 8, 2024


/s/ William Morachnick

William Morachnick

Chief Executive Officer

(Principal Executive Officer)

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Charlotte's Web Holdings, Inc. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2024, as filed with the Securities and Exchange Commission (the "Report"), I, Erika Lind, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

Dated: August 8, 2024


/s/ Erika Lind

Erika Lind

Chief Financial Officer

(Principal Financial Officer)

COVER PAGE - shares	6 Months Ended
COVER PAGE - shares	Jun. 30, 2024	Aug. 06, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	000-56364
Entity Registrant Name	Charlotte's Web Holdings, Inc.
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	98-1508633
Entity Address, Address Line One	700 Tech Court
Entity Address, City or Town	Louisville
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80027
City Area Code	720
Local Phone Number	484-8930
Title of 12(g) Security	Common stock, no par value
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		157,495,042
Amendment Flag	false
Entity Central Index Key	0001750155
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 32,531	$ 47,820
Accounts receivable, net	1,869	1,950
Inventories, net	18,673	21,538
Prepaid expenses and other current assets	3,857	6,864
Total current assets	56,930	78,172
Property and equipment, net	28,198	27,513
License and media rights	16,590	17,070
Operating lease right-of-use assets, net	13,740	14,601
Investment in unconsolidated entity	11,200	11,000
SBH purchase option and other derivative assets	1,436	2,602
Intangible assets, net	1,166	887
Other long-term assets	534	703
Total assets	129,794	152,548
Current liabilities:
Accounts payable	4,350	2,860
Accrued and other current liabilities	6,669	8,682
Lease obligations – current	2,376	2,252
License and media rights payable - current	5,072	9,852
Total current liabilities	18,467	23,646
Convertible debenture	43,455	42,528
Lease obligations	14,456	15,655
License and media rights payable	14,093	11,338
Derivatives and other long-term liabilities	3,495	3,823
Total liabilities	93,966	96,990
Commitments and contingencies (Note 7)
Shareholders’ equity:
Common shares, nil par value; unlimited shares authorized; 157,495,042 and 154,332,366 shares issued and outstanding as of June 30, 2024 and December 31, 2023	1	1
Additional paid-in capital	328,241	327,280
Accumulated deficit	(292,414)	(271,723)
Total shareholders’ equity	35,828	55,558
Total liabilities and shareholders’ equity	$ 129,794	$ 152,548

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common shares, issued (in shares)	157,495,042	154,332,366
Common shares, outstanding (in shares)	157,495,042	154,332,366

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	$ 12,289	$ 16,006	$ 24,413	$ 33,016
Cost of goods sold	9,707	7,088	14,920	14,181
Gross profit	2,582	8,918	9,493	18,835
Selling, general and administrative expenses	14,727	19,627	30,007	37,140
Operating loss	(12,145)	(10,709)	(20,514)	(18,305)
Gain on initial investment in unconsolidated entity	0	10,700	0	10,700
Change in fair value of financial instruments	1,140	4,229	(720)	9,612
Other income (expense), net	(6)	(1,376)	605	(2,074)
Income (loss) before provision for income taxes	(11,011)	2,844	(20,629)	(67)
Income tax benefit (expense)	(46)	0	(62)	0
Net income (loss)	$ (11,057)	$ 2,844	$ (20,691)	$ (67)
Per common share amounts (Note 10)
Net income (loss) per common share, basic (in usd per share)	$ (0.07)	$ 0.02	$ (0.13)	$ 0
Net income (loss) per common share, diluted (in usd per share)	$ (0.07)	$ 0.02	$ (0.13)	$ 0

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Restricted Stock Units (RSUs)	Common Shares	Common Shares Restricted Stock Units (RSUs)	Additional Paid-in Capital	Additional Paid-in Capital Restricted Stock Units (RSUs)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022			152,135,026
Beginning balance at Dec. 31, 2022	$ 77,505		$ 1		$ 325,431		$ (247,927)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued upon vesting of restricted share units, net of withholding (in shares)				297,888
Common shares issued upon vesting of restricted share units, net of withholding		$ (69)				$ (69)
Share-based compensation	375				375
Net income (loss)	(2,912)						(2,912)
Ending balance (in shares) at Mar. 31, 2023			152,432,914
Ending balance at Mar. 31, 2023	74,899		$ 1		325,737		(250,839)
Beginning balance (in shares) at Dec. 31, 2022			152,135,026
Beginning balance at Dec. 31, 2022	77,505		$ 1		325,431		(247,927)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(67)
Ending balance (in shares) at Jun. 30, 2023			152,825,118
Ending balance at Jun. 30, 2023	78,361		$ 1		326,355		(247,995)
Beginning balance (in shares) at Mar. 31, 2023			152,432,914
Beginning balance at Mar. 31, 2023	74,899		$ 1		325,737		(250,839)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued upon vesting of restricted share units, net of withholding (in shares)				392,204
Common shares issued upon vesting of restricted share units, net of withholding		(6)				(6)
Share-based compensation	624				624
Net income (loss)	2,844						2,844
Ending balance (in shares) at Jun. 30, 2023			152,825,118
Ending balance at Jun. 30, 2023	$ 78,361		$ 1		326,355		(247,995)
Beginning balance (in shares) at Dec. 31, 2023	154,332,366		154,332,366
Beginning balance at Dec. 31, 2023	$ 55,558		$ 1		327,280		(271,723)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued upon vesting of restricted share units, net of withholding (in shares)				2,895,489
Common shares issued upon vesting of restricted share units, net of withholding		(98)				(98)
Share-based compensation	842				842
Net income (loss)	(9,634)						(9,634)
Ending balance (in shares) at Mar. 31, 2024			157,227,855
Ending balance at Mar. 31, 2024	$ 46,668		$ 1		328,024		(281,357)
Beginning balance (in shares) at Dec. 31, 2023	154,332,366		154,332,366
Beginning balance at Dec. 31, 2023	$ 55,558		$ 1		327,280		(271,723)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (20,691)
Ending balance (in shares) at Jun. 30, 2024	157,495,042		157,495,042
Ending balance at Jun. 30, 2024	$ 35,828		$ 1		328,241		(292,414)
Beginning balance (in shares) at Mar. 31, 2024			157,227,855
Beginning balance at Mar. 31, 2024	46,668		$ 1		328,024		(281,357)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued upon vesting of restricted share units, net of withholding (in shares)				267,187
Common shares issued upon vesting of restricted share units, net of withholding		$ (20)				$ (20)
Share-based compensation	237				237
Net income (loss)	$ (11,057)						(11,057)
Ending balance (in shares) at Jun. 30, 2024	157,495,042		157,495,042
Ending balance at Jun. 30, 2024	$ 35,828		$ 1		$ 328,241		$ (292,414)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (20,691)	$ (67)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,982	7,769
Inventory provision	3,926	320
Convertible debenture accrued interest	1,931	1,954
Share-based compensation	1,079	999
Changes in right-of-use assets	908	976
Change in fair value of financial instruments	720	(9,612)
Gain on investment in unconsolidated entity	0	(10,700)
(Gain)/loss on foreign currency transaction	(1,430)	979
Other	238	957
Changes in operating assets and liabilities:
Accounts receivable, net	(154)	(1,104)
Inventories, net	(1,025)	2,878
Prepaid expenses and other current assets	1,732	764
Accounts payable, accrued and other liabilities	(286)	183
Operating lease obligations	(1,121)	(1,436)
License and media rights	(2,500)	(4,000)
Income taxes receivable	0	4,261
Other operating assets and liabilities, net	(192)	(130)
Net cash used in operating activities	(11,883)	(5,009)
Cash flows from investing activities:
Purchases of property and equipment and intangible assets	(3,316)	(187)
Proceeds from sale of assets	28	36
Net cash used in investing activities	(3,288)	(151)
Cash flows from financing activities:
Other financing activities	(118)	(75)
Net cash used in financing activities	(118)	(75)
Net decrease in cash and cash equivalents	(15,289)	(5,235)
Cash and cash equivalents —beginning of period	47,820	66,963
Cash and cash equivalents —end of period	32,531	61,728
Non-cash activities:
Non-cash purchase of property and equipment and intangible assets	(269)	(163)
Non-cash issuance of note receivable	$ 0	$ (156)

DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS	DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS Description of the Business Charlotte's Web Holdings, Inc. together with its subsidiaries (collectively "Charlotte's Web" or the "Company") is a public company incorporated pursuant to the laws of the Province of British Columbia and a Certified B Corp. The Company's common shares are publicly listed on the Toronto Stock Exchange ("TSX") under the symbol "CWEB" and quoted on the OTCQX under the symbol "CWBHF." The Company's corporate headquarters is located in Louisville, Colorado in the United States of America. The majority of the Company's business is conducted in the United States of America. The Company's primary products are made from proprietary strains of whole-plant hemp extracts containing a full spectrum of phytocannabinoids, terpenes, flavonoids and other hemp compounds. Hemp extracts are produced from the plant Cannabis sativa L. ("Cannabis"), and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol ("THC") concentration of not more than 0.3% on a dry weight basis ("Hemp"). The Company is engaged in research involving the effectiveness of a broad variety of compounds derived from Hemp. The Company does not currently produce or sell medical or recreational marijuana or products derived from high THC Cannabis plants. The Company does not currently have any plans to expand into such high THC products in the near future. The Company's current product categories include full spectrum hemp extract oil tinctures (liquid product), gummies, capsules, soft-gels, CBD topical creams and lotions, and pet products. The Company's products are distributed through its e-commerce website, third-party e-commerce websites, select distributors, health practitioners, and a variety of brick-and-mortar specialty retailers. The Company grows its proprietary hemp domestically in the United States on farms leased in northeastern Colorado and sources hemp through contract farming operations in Arizona, Colorado, Kentucky, Oregon, and Canada. The Hemp grown in Canada is utilized exclusively in the Canadian markets or for research purposes and not in products sold within the United States. In furtherance of the Company's research and development ("R&D") efforts, the Company established CW Labs, an internal division for R&D, to expand the Company's efforts around the science of hemp derived compounds. CW Labs is currently engaged in clinical trials addressing Hemp-based health solutions. CW Labs is located in Louisville, Colorado at the Company's current good manufacturing practice ("cGMP") production and distribution facility.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

Basis of Presentation

Inventories

Revenue Recognition


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Direct-to-consumer	$	7,820	$	10,734	$	15,592	$	22,002
Business-to-business	4,395		5,272		8,436		11,014
Service revenue	74		—		385		—
Total	$	12,289	$	16,006	$	24,413	$	33,016

Substantially all of the Company's revenue is earned in the United States.

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

Other than described below, no new accounting pronouncements issued by the FASB may have a material impact on the Company's consolidated financial statements and related disclosures.

FAIR VALUE MEASUREMENT

6 Months Ended

Jun. 30, 2024

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENT


	June 30, 2024
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	745	$	745
Debt interest rate conversion feature	—		—		691		691
Total financial assets	$	—	$	—	$	1,436	$	1,436

Investment in unconsolidated entity:	$	—	$	—	$	11,200	$	11,200

Financial liabilities:
Debt conversion option	$	—	$	2,892	$	—	$	2,892


	December 31, 2023
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	1,730	$	1,730
Debt interest rate conversion feature	—		—		872		$	872
Total financial assets	$	—	$	—	$	2,602	$	2,602

Investment in unconsolidated entity:	$	—	$	—	$	11,000	$	11,000

Financial liabilities:
Debt conversion option	$	—	$	3,213	$	—	3,213

There were no transfers between levels of the fair value hierarchy during the three and six month periods ended June 30, 2024 and the year ended December 31, 2023.

Investment in Unconsolidated Entity

expected to use the investments for the clinical development of a hemp botanical Investigational New Drug application and has commenced Phase I clinical development.

The following additional assumptions are used in the model:


	June 30,	December 31,
	2024	2023
Expected term (years)	5.8	6.3
Volatility	77.0%	70.0%
Risk-free interest rate	4.3%	3.9%
Expected dividend yield	—%	—%
Discount for lack of marketability	31.0%	20.0%

Convertible Debt Derivatives

Debt Interest Rate Conversion Feature


	June 30,	December 31,
	2024	2023
Stated interest rate	5.0%	5.0%
Adjusted interest rate	1.5%	1.5%
Implied debt yield	16.3%	11.0%
Federal regulation probability	Various	Various
Year of event	Various	Various

Debt Conversion Option

interest rate is based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the expected maturity of the debenture.

The following table provides the assumption regarding Level 2 fair value measurements inputs at their measurement dates:


	June 30,	December 31,
	2024	2023
Expected volatility	88.0%	87.4%
Expected term (years)	5.4	5.9
Risk-free interest rate	4.3%	3.9%
Expected dividend yield	—%	—%
Value of underlying share	C$0.27	C$0.27
Exercise price	C$2.00	C$2.00

Stanley Brothers USA Holdings Purchase Option


	June 30,	December 31,
	2024	2023
Expected volatility	125.0%	125.0%
Expected term (years)	1.7	2.2
Risk-free interest rate	4.9%	4.2%
Weighted average cost of capital	51.8%	50.6%

INVENTORIES

6 Months Ended

Jun. 30, 2024

Inventory Disclosure [Abstract]

INVENTORIES

Inventories consist of the following:


	June 30,		December 31,
	2024		2023
Harvested hemp and seeds	$	8,009	$	9,300
Raw materials	12,153		9,726
Finished goods	5,751		6,320
	25,913		25,346
Less: inventory provision	(7,240)		(3,808)
Total inventory	$	18,673	$	21,538

Inventory Provision

LICENSE AND MEDIA RIGHTS

6 Months Ended

Jun. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

LICENSE AND MEDIA RIGHTS

MLB Promotion Rights Agreement

The MLB First Amendment agreement extended the maturities of the future payment by an additional 2 years. Maturities of the MLB license and media rights payable as of June 30, 2024 are as follows:


2024 (6 months remaining)	$	2,500
2025	5,500
2026	6,000
2027	6,500
Total payments	$	20,500
Less: Imputed interest	(1,335)
Total license and media rights payable	$	19,165
Less: Current license liabilities	(5,072)
Total non-current license and media rights payable	$	14,093

As of June 30, 2024, expected amortization of licensed properties are as follows:


2024 (6 months remaining)	$	1,949
2025	3,897
2026	3,897
2027	3,897
Total future amortization	$	13,640

DEBT

6 Months Ended

Jun. 30, 2024

Debt Disclosure [Abstract]

DEBT

Convertible Debenture

The following is a summary of the Company's convertible debenture as of June 30, 2024:


	As of June 30, 2024
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	59,668	$	(16,213)	$	43,455

The following is a summary of the Company's convertible debenture as of December 31, 2023:


	As of December 31, 2023
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	60,116	$	(17,588)	$	42,528


	Three Months Ended June 30,				Six Months Ended June 30,
Interest and Amortization Expense	2024		2023		2024		2023
Interest expense	$	721	$	701	$	1,454	$	1,398
Amortization of debt discounts and costs	427		349		828		668
Total	$	1,148	$	1,050	$	2,282	$	2,066

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Contingencies From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of June 30, 2024 there is no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company’s financial position, results of operations or cash flows.

LEASES

6 Months Ended

Jun. 30, 2024

Leases [Abstract]

LEASES

Maturities of operating lease liabilities as of June 30, 2024 are as follows:


	Operating Leases
2024 (6 months remaining)	$	1,640
2025	2,892
2026	2,169
2027	1,844
2028	1,762
Thereafter	11,884
Total lease obligation	22,191
Less: Imputed interest	(5,359)
Total lease liabilities	16,832
Less: Current lease liabilities	(2,376)
Total non-current lease liabilities	$	14,456

SHAREHOLDERS’ EQUITY	6 Months Ended
SHAREHOLDERS’ EQUITY	Jun. 30, 2024
Equity [Abstract]
SHAREHOLDERS’ EQUITY	SHAREHOLDERS’ EQUITY As of June 30, 2024 and December 31, 2023, the Company’s share capital consists of one class of issued and outstanding shares: common shares. The Company is also authorized to issue preferred shares issuable in series. To date, no shares of preferred shares have been issued or are outstanding. Common Shares As of June 30, 2024 and December 31, 2023, the Company was authorized to issue an unlimited number of common shares, which have no par value.

INCOME (LOSS) PER SHARE

6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

INCOME (LOSS) PER SHARE

The following table sets forth the computation of basic and dilutive net income (loss) per share attributable to common shareholders:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Net income (loss)	$	(11,057)	$	2,844	$	(20,691)	$	(67)
Weighted-average number of common shares - basic	157,227,855		152,481,470		156,632,263		152,398,273
Dilutive effect of securities	—		278,618		—		—
Weighted-average number of common shares - diluted	157,227,855		152,760,088		156,632,263		152,398,273
Income (loss) per common share – basic	$	(0.07)	$	0.02	$	(0.13)	$	—
Income (loss) per common share – diluted	$	(0.07)	$	0.02	$	(0.13)	$	—


	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Outstanding options	4,523,486	7,012,707	4,523,486	7,012,707
Outstanding restricted share units	5,583,322	2,398,844	5,583,322	2,677,462
Total	10,106,808	9,411,551	10,106,808	9,690,169

STOCK-BASED COMPENSATION

6 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

Stock options


									Six Months Ended June 30,
									2023
Expected volatility									88.8%
Expected term (years)									5.5-6.5
Risk-free interest rate									3.4%
Expected dividend yield									0%
Value of underlying share									$0.36


	Number of Options	Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contract Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	5,780,134	$	0.75	8.56	$	—
Granted	—	—
Exercised	—	—
Forfeited (and expired)	(1,256,648)	0.50
Outstanding as of June 30, 2024	4,523,486	$	0.83	7.94	$	—

Exercisable/vested as of June 30, 2024	3,442,986	$	0.89	7.69	$	—

There were no options granted during the six months ended June 30, 2024. The weighted average grant-date fair value of options granted during the six months ended June 30, 2023 was $0.38.

There were no options exercised during the six months ended June 30, 2024 and 2023.

Restricted share units

Details of the number of restricted share units outstanding under the 2018 Plan is as follows:


	Number of Shares	Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2023	7,250,766	$	0.31
Granted	3,021,276	$	0.21
Forfeited	(898,685)	$	0.24
Vested	(3,162,676)	$	0.30
Shares withheld upon vesting	(627,359)	$	0.49
Outstanding as of June 30, 2024	5,583,322	$	0.26

Share-based Compensation Expense

INCOME TAXES	6 Months Ended
INCOME TAXES	Jun. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company reported income tax expense of $46 and $0 for the three months ended June 30, 2024 and 2023, respectively. Additionally, income tax expense for the six months ended June 30, 2024 and 2023 was of $62 and $0, respectively.The Company's effective tax rate for the three and six months ended June 30, 2024 and June 30, 2023 was 0.2% and 0%. The Company’s effective tax rates differ from the U.S. federal statutory rate of 21% for the three and six months end June 30, 2024 and June 30, 2023, respectively, primarily due to the valuation allowance. The effective tax rate for the three and six months ended June 30, 2024 is consistent with the three and six months ended June 30, 2023, as the Company has been in a full valuation allowance for both periods.

RELATED PARTY TRANSACTIONS	6 Months Ended
RELATED PARTY TRANSACTIONS	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Effective November 2020, the Company issued a secured promissory note, where $1,000 was loaned to one of the Company's founders. The note receivable was secured by equity instruments with certain founders of the Company, bore interest at 3.25% per annum, and required the unpaid principal and unpaid interest balances to be paid on or before the maturity date of November 13, 2021. Effective December 28, 2023, the Company entered into a second amendment of the promissory note to extend the maturity date until November 13, 2024. According to the terms of the agreement, no additional interest will accrue through the payment date. The note has been fully reserved for as of December 31, 2023. On March 2, 2021, the Company entered into the SBH Purchase Option with Stanley Brothers USA as discussed above (Note 3 "Fair Value Measurement"). The SBH Purchase Option was purchased for total consideration of $8,000. Certain founders of the Company, who are or were employees at the time, are the majority shareholders of Stanley Brothers USA. On April 6, 2023, the Company jointly formed an entity, DeFloria, with AJNA and BAT. AJNA is a botanical drug development company. AJNA is partially owned and was co-founded by a co-founder of Charlotte's Web. BAT holds an equity interest in the entity in the form of 200,000 preferred units following its initial $10 million investment and has the right to participate in future equity issuances to maintain its pro rata equity position. The Company and AJNA each hold 400,000 of the entity's voting common units (Note 3). Effective May 1, 2023, the Company entered into an 8% interest bearing note receivable with DeFloria for the sale of lab equipment in the amount of $170. The principal and interest of the note receivable will be paid in 36 monthly installments. As of June 30, 2024, the remaining note receivable of $99, is presented in other assets in the condensed consolidated balance sheets. In 2024, BAT and AJNA invested an additional $5 million and $2 million, respectively, in DeFloria in the form of convertible debt (refer to Note 3). Additionally, on February 12, 2024, the Company and DeFloria entered into a separate master services agreement pursuant to which the Company will be compensated for the provision of certain services to DeFloria. For the three and six months ended June 30, 2024, the Company recognized $74 and $385 in revenue and cost of goods sold, respectively, related to the service agreement with DeFloria. Additionally, the Company has an accounts receivable balance due from DeFloria of $74, for the three and six months ended June 30, 2024, respectively. On June 21, 2024, the Company entered into a consulting agreement with Jared Stanley, Co-Founder of Charlotte's Web, former executive of the Company, and current member of the Board of Directors. The consulting agreement will remain in effect until June 13, 2025. In consideration for Mr. Stanley's services, he will receive a bi-weekly fee of $6.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net income (loss)	$ (11,057)	$ (9,634)	$ 2,844	$ (2,912)	$ (20,691)	$ (67)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB"). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company's financial position as of June 30, 2024 and its results of operations for the three and six months ended June 30, 2024 and 2023, cash flows for the six months ended June 30, 2024 and 2023, and stockholders' equity for the three and six months ended June 30, 2024 and 2023. Operating results for the three and six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024. The unaudited interim condensed consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual consolidated financial statements. Certain amounts presented in prior periods have been reclassified to conform with the current period presentation. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2024.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. The Company's inventory production process for cannabinoid products includes the cultivation of botanical raw material. Due to the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset.
Revenue Recognition	Revenue Recognition The majority of the Company's revenue is derived from sales of branded products to consumers via the Company's direct-to-consumer e-commerce website, as well as distributors, retail and wholesale business-to-business customers. Additionally, on February 12, 2024, the Company and DeFloria LLC ("DeFloria") entered into a Master Services Agreement ("Services Agreement") pursuant to which the Company is compensated for the provision of certain services to DeFloria.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements There are no new recent accounting pronouncements that have been issued by the Financial Accounting Standards Board ("FASB") and adopted by the Company had or may have a material impact on the accompanying unaudited interim condensed consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted Other than described below, no new accounting pronouncements issued by the FASB may have a material impact on the Company's consolidated financial statements and related disclosures. On December 14, 2023, the FASB issued a final standard on improvements to income tax disclosures, ASU 2023-09, Improvements to Income Tax Disclosures. The standard requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. For public business entities, the new requirements will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact, if any, that the updated standard will have on the Company's consolidated financial statements and related disclosures. On November 27, 2023, the FASB issued ASU 2023-07—Segment Reporting. The new guidance was issued primarily to provide financial statement users with more disaggregated expense information about a public entity's reportable segments. The guidance is effective for calendar year public entities in 2024 year-end financial statements and should be adopted retrospectively unless impracticable. The Company is currently evaluating the impact, if any, that the updated standard will have on the Company's consolidated financial statements and related disclosures.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Schedule of Disaggregation of Revenue

The following table sets forth the disaggregation of the Company's revenue:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Direct-to-consumer	$	7,820	$	10,734	$	15,592	$	22,002
Business-to-business	4,395		5,272		8,436		11,014
Service revenue	74		—		385		—
Total	$	12,289	$	16,006	$	24,413	$	33,016

FAIR VALUE MEASUREMENT (Tables)

6 Months Ended

Jun. 30, 2024

Fair Value Disclosures [Abstract]

Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis


	June 30, 2024
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	745	$	745
Debt interest rate conversion feature	—		—		691		691
Total financial assets	$	—	$	—	$	1,436	$	1,436

Investment in unconsolidated entity:	$	—	$	—	$	11,200	$	11,200

Financial liabilities:
Debt conversion option	$	—	$	2,892	$	—	$	2,892


	December 31, 2023
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	1,730	$	1,730
Debt interest rate conversion feature	—		—		872		$	872
Total financial assets	$	—	$	—	$	2,602	$	2,602

Investment in unconsolidated entity:	$	—	$	—	$	11,000	$	11,000

Financial liabilities:
Debt conversion option	$	—	$	3,213	$	—	3,213

Schedule of Fair Value Measurement Joint Venture and Additional Assumptions Used in Debt Interest Rate Conversion Option and Assumption Regarding Level 2 Fair Value Measurements Inputs and Assumptions Used in the Model of SBH Purchase Option

The following additional assumptions are used in the model:


	June 30,	December 31,
	2024	2023
Expected term (years)	5.8	6.3
Volatility	77.0%	70.0%
Risk-free interest rate	4.3%	3.9%
Expected dividend yield	—%	—%
Discount for lack of marketability	31.0%	20.0%

The following additional assumptions are used in the model:


	June 30,	December 31,
	2024	2023
Stated interest rate	5.0%	5.0%
Adjusted interest rate	1.5%	1.5%
Implied debt yield	16.3%	11.0%
Federal regulation probability	Various	Various
Year of event	Various	Various

The following table provides the assumption regarding Level 2 fair value measurements inputs at their measurement dates:


	June 30,	December 31,
	2024	2023
Expected volatility	88.0%	87.4%
Expected term (years)	5.4	5.9
Risk-free interest rate	4.3%	3.9%
Expected dividend yield	—%	—%
Value of underlying share	C$0.27	C$0.27
Exercise price	C$2.00	C$2.00

The following additional assumptions are used in the fair value model of the SBH Purchase Option:


	June 30,	December 31,
	2024	2023
Expected volatility	125.0%	125.0%
Expected term (years)	1.7	2.2
Risk-free interest rate	4.9%	4.2%
Weighted average cost of capital	51.8%	50.6%

INVENTORIES (Tables)

6 Months Ended

Jun. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:


	June 30,		December 31,
	2024		2023
Harvested hemp and seeds	$	8,009	$	9,300
Raw materials	12,153		9,726
Finished goods	5,751		6,320
	25,913		25,346
Less: inventory provision	(7,240)		(3,808)
Total inventory	$	18,673	$	21,538

LICENSE AND MEDIA RIGHTS (Tables)

6 Months Ended

Jun. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Schedule of Maturities of MLB License and Media Rights Payable

Maturities of the MLB license and media rights payable as of June 30, 2024 are as follows:


2024 (6 months remaining)	$	2,500
2025	5,500
2026	6,000
2027	6,500
Total payments	$	20,500
Less: Imputed interest	(1,335)
Total license and media rights payable	$	19,165
Less: Current license liabilities	(5,072)
Total non-current license and media rights payable	$	14,093

Schedule of Expected Amortization of Licensed Properties

As of June 30, 2024, expected amortization of licensed properties are as follows:


2024 (6 months remaining)	$	1,949
2025	3,897
2026	3,897
2027	3,897
Total future amortization	$	13,640

DEBT (Tables)

6 Months Ended

Jun. 30, 2024

Debt Disclosure [Abstract]

Schedule of Convertible Debenture

The following is a summary of the Company's convertible debenture as of June 30, 2024:


	As of June 30, 2024
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	59,668	$	(16,213)	$	43,455

The following is a summary of the Company's convertible debenture as of December 31, 2023:


	As of December 31, 2023
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	60,116	$	(17,588)	$	42,528

Schedule of Interest Expense

The following is a summary of the interest expense and amortization expense, recorded within the statement of operation, of the Company's convertible debenture for the three and six months ended June 30, 2024 and June 30, 2023:


	Three Months Ended June 30,				Six Months Ended June 30,
Interest and Amortization Expense	2024		2023		2024		2023
Interest expense	$	721	$	701	$	1,454	$	1,398
Amortization of debt discounts and costs	427		349		828		668
Total	$	1,148	$	1,050	$	2,282	$	2,066

LEASES (Tables)

6 Months Ended

Jun. 30, 2024

Leases [Abstract]

Schedule of Maturities of Operating Lease Liabilities

Maturities of operating lease liabilities as of June 30, 2024 are as follows:


	Operating Leases
2024 (6 months remaining)	$	1,640
2025	2,892
2026	2,169
2027	1,844
2028	1,762
Thereafter	11,884
Total lease obligation	22,191
Less: Imputed interest	(5,359)
Total lease liabilities	16,832
Less: Current lease liabilities	(2,376)
Total non-current lease liabilities	$	14,456

INCOME (LOSS) PER SHARE (Tables)

6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Dilutive Net Income (Loss) Per Share

The following table sets forth the computation of basic and dilutive net income (loss) per share attributable to common shareholders:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Net income (loss)	$	(11,057)	$	2,844	$	(20,691)	$	(67)
Weighted-average number of common shares - basic	157,227,855		152,481,470		156,632,263		152,398,273
Dilutive effect of securities	—		278,618		—		—
Weighted-average number of common shares - diluted	157,227,855		152,760,088		156,632,263		152,398,273
Income (loss) per common share – basic	$	(0.07)	$	0.02	$	(0.13)	$	—
Income (loss) per common share – diluted	$	(0.07)	$	0.02	$	(0.13)	$	—

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

As such, for the three and six months ended June 30, 2024 and for the six months ended June 30, 2023, all potentially dilutive shares have been excluded. When the Company recognizes net income from continuing operations, the Company computes the effect of dilutive securities using the treasury stock method and average market prices during the period.


	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Outstanding options	4,523,486	7,012,707	4,523,486	7,012,707
Outstanding restricted share units	5,583,322	2,398,844	5,583,322	2,677,462
Total	10,106,808	9,411,551	10,106,808	9,690,169

SHARE-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Principal Inputs Used in Valuation of Awards Issued

The following principal inputs were used in the valuation of awards issued for the six months ended June 30, 2023:


									Six Months Ended June 30,
									2023
Expected volatility									88.8%
Expected term (years)									5.5-6.5
Risk-free interest rate									3.4%
Expected dividend yield									0%
Value of underlying share									$0.36

Schedule of Stock Option Activity


	Number of Options	Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contract Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	5,780,134	$	0.75	8.56	$	—
Granted	—	—
Exercised	—	—
Forfeited (and expired)	(1,256,648)	0.50
Outstanding as of June 30, 2024	4,523,486	$	0.83	7.94	$	—

Exercisable/vested as of June 30, 2024	3,442,986	$	0.89	7.69	$	—

Schedule of Restricted Stock Units

Details of the number of restricted share units outstanding under the 2018 Plan is as follows:


	Number of Shares	Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2023	7,250,766	$	0.31
Granted	3,021,276	$	0.21
Forfeited	(898,685)	$	0.24
Vested	(3,162,676)	$	0.30
Shares withheld upon vesting	(627,359)	$	0.49
Outstanding as of June 30, 2024	5,583,322	$	0.26

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 12,289	$ 16,006	$ 24,413	$ 33,016
Direct-to-consumer
Disaggregation of Revenue [Line Items]
Revenue	7,820	10,734	15,592	22,002
Business-to-business
Disaggregation of Revenue [Line Items]
Revenue	4,395	5,272	8,436	11,014
Service revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 74	$ 0	$ 385	$ 0

FAIR VALUE MEASUREMENT - Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Financial assets:
Stanley Brothers USA Holdings purchase option	$ 745	$ 1,730
Debt interest rate conversion feature	691	872
Total financial assets	1,436	2,602
Investment in unconsolidated entity:	11,200	11,000
Financial liabilities:
Debt conversion option	2,892	3,213
Level 1
Financial assets:
Stanley Brothers USA Holdings purchase option	0	0
Debt interest rate conversion feature	0	0
Total financial assets	0	0
Investment in unconsolidated entity:	0	0
Financial liabilities:
Debt conversion option	0	0
Level 2
Financial assets:
Stanley Brothers USA Holdings purchase option	0	0
Debt interest rate conversion feature	0	0
Total financial assets	0	0
Investment in unconsolidated entity:	0	0
Financial liabilities:
Debt conversion option	2,892	3,213
Level 3
Financial assets:
Stanley Brothers USA Holdings purchase option	745	1,730
Debt interest rate conversion feature	691	872
Total financial assets	1,436	2,602
Investment in unconsolidated entity:	11,200
Financial liabilities:
Debt conversion option	$ 0	$ 0

FAIR VALUE MEASUREMENT - Narrative (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Millions		3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 02, 2021 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 USD ($)	Apr. 06, 2023 USD ($) $ / shares shares	Nov. 14, 2022 USD ($)	Nov. 14, 2022 CAD ($) $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Gain on initial investment in unconsolidated entity		$ 0	$ 10,700	$ 0	$ 10,700
Gain on fair value of financial instruments		1,140	4,229	(720)	9,612
Investment in unconsolidated entity		11,200		11,200			$ 11,000
Debt interest rate conversion feature		691		691			872
Derivative liability, noncurrent		2,892		2,892			3,213
Purchase option	$ 8,000					$ 8,000
Purchase option, term						5 years
Extension, term						2 years
Percentage of outstanding shares						10.00%
Warrants expiration period						60 days
Gain (loss) on change in fair value of purchase option		(34)	57	(985)	(243)
Financial asset, purchase option		745		745			1,730
BAT Group
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Convertible ownership percentage									19.90%	19.90%
Conversion price (in CAD per share) \| $ / shares										$ 2.00
BAT Group \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Accrued interest rate, percentage									5.00%	5.00%
BAT Group \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Accrued interest rate, percentage									1.50%	1.50%
BAT Group \| Convertible Notes Payable
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Principal Amount		59,668		59,668			60,116		$ 56,800	$ 75.3
DeFloria, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Equity method ownership percentage								50.00%
British American Tobacco \| DeFloria, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Preferred units ownership percentage								100.00%
AJNA Biosciences \| DeFloria, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Equity method ownership percentage								50.00%
DeFloria, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Common units (in shares) \| shares								400,000
Gain on fair value of financial instruments		1,000	0	200	0
Investment in unconsolidated entity		11,200		11,200			11,000
DeFloria, LLC \| Class A Common Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding (in shares) \| shares								865,052
Warrants exercise price (in USD per share) \| $ / shares								$ 2.89
DeFloria, LLC \| British American Tobacco
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Preferred units (in shares) \| shares								200,000
Capital contributed								$ 10,000
Payment for convertible debt				5,000
DeFloria, LLC \| AJNA Biosciences
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Payment for convertible debt				2,000
Common units (in shares) \| shares								400,000
Debt Conversion Option
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unrealized gain (loss) on hedging instruments		276	4,066	220	10,361
Derivative liability, noncurrent		2,892		2,892			3,213
Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investment in unconsolidated entity		11,200		11,200
Debt interest rate conversion feature		691		691			872
Derivative liability, noncurrent		0		0			0
Financial asset, purchase option		745		745			$ 1,730
Debt Interest Rate Conversion Feature
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unrealized gain (loss) on hedging instruments		$ (101)	$ 106	$ (154)	$ (506)

FAIR VALUE MEASUREMENT - Schedule of Fair Value Measurement Joint Venture (Details) - DeFloria, LLC	Jun. 30, 2024 year	Dec. 31, 2023 year
Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	5.8	6.3
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	0.770	0.700
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	0.043	0.039
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	0	0
Discount for lack of marketability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	0.310	0.200

FAIR VALUE MEASUREMENT - Schedule of Additional Assumptions Used in Debt Interest Rate Conversion Option (Details) - Level 3	Jun. 30, 2024	Dec. 31, 2023
Stated interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.050	0.050
Adjusted interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.015	0.015
Implied debt yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.163	0.110

FAIR VALUE MEASUREMENT - Schedule of Assumption Regarding Level 2 Fair Value Measurements Inputs (Details) - Level 2	Jun. 30, 2024 $ / shares	Dec. 31, 2023 $ / shares
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.880	0.874
Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	5.4	5.9
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.043	0.039
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0	0
Value of underlying share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.27	0.27
Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	2.00	2.00

FAIR VALUE MEASUREMENT - Schedule of Assumptions Used in the Model of SBH Purchase Option (Details)	Jun. 30, 2024 year	Dec. 31, 2023 year
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	1.250	1.250
Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	1.7	2.2
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	0.049	0.042
Weighted average cost of capital
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	0.518	0.506

INVENTORIES - Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Harvested hemp and seeds	$ 8,009	$ 9,300
Raw materials	12,153	9,726
Finished goods	5,751	6,320
Inventory, gross	25,913	25,346
Less: inventory provision	(7,240)	(3,808)
Inventories, net	$ 18,673	$ 21,538

INVENTORIES - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
INVENTORIES - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventory provision	$ 3,926	$ 320

LICENSE AND MEDIA RIGHTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Other Commitments [Line Items]
Carrying value of licensed properties	$ 13,640		$ 13,640		$ 14,589
Carrying value of media rights	3,950		3,950		$ 4,982
Licensing Agreements
Other Commitments [Line Items]
Amortization	1,025	$ 2,074	1,999	$ 3,897
Major League Baseball Properties Inc \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Payments for license fee	$ 0	$ 2,000	$ 2,500	$ 4,000
Collaborative arrangement, rights and obligations, extension term			2 years

LICENSE AND MEDIA RIGHTS - Schedule of Maturities of MLB License and Media Rights Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Other Commitments [Line Items]
Less: Current license liabilities	$ (5,072)	$ (9,852)
Total non-current license and media rights payable	14,093	$ 11,338
Licensing Agreements
Other Commitments [Line Items]
2024 (6 months remaining)	2,500
2025	5,500
2026	6,000
2027	6,500
Total payments	20,500
Less: Imputed interest	(1,335)
Total license and media rights payable	19,165
Less: Current license liabilities	(5,072)
Total non-current license and media rights payable	$ 14,093

LICENSE AND MEDIA RIGHTS - Schedule of Expected Amortization of Licensed Properties (Details) - Licensing Agreements $ in Thousands	Jun. 30, 2024 USD ($)
Other Commitments [Line Items]
2024 (6 months remaining)	$ 1,949
2025	3,897
2026	3,897
2027	3,897
Total future amortization	$ 13,640

DEBT - Narrative (Details) - BAT Group $ / shares in Units, $ in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Nov. 14, 2022 USD ($)	Nov. 14, 2022 CAD ($) $ / shares
Line of Credit Facility [Line Items]
Convertible ownership percentage						19.90%	19.90%
Conversion price (in CAD per share) \| $ / shares							$ 2.00
Accrued interest expense	$ 4,636	$ 1,777	$ 4,636	$ 1,777
Convertible Notes Payable
Line of Credit Facility [Line Items]
Principal Amount	59,668		59,668		$ 60,116	$ 56,800	$ 75.3
Foreign currency gain (loss)	$ 430	$ (831)	$ 1,355	$ (820)
Minimum
Line of Credit Facility [Line Items]
Accrued interest rate, percentage						5.00%	5.00%
Maximum
Line of Credit Facility [Line Items]
Accrued interest rate, percentage						1.50%	1.50%

DEBT - Schedule of Convertible Debenture (Details) - BAT Group - Convertible Notes Payable $ in Thousands, $ in Millions	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Nov. 14, 2022 USD ($)	Nov. 14, 2022 CAD ($)
Line of Credit Facility [Line Items]
Principal Amount	$ 59,668	$ 60,116	$ 56,800	$ 75.3
Unamortized Debt Discount and Costs	(16,213)	(17,588)
Net Carrying Amount	$ 43,455	$ 42,528

DEBT - Schedule of Interest Expense (Details) - BAT Group - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Line of Credit Facility [Line Items]
Interest expense	$ 721	$ 701	$ 1,454	$ 1,398
Amortization of debt discounts and costs	427	349	828	668
Total	$ 1,148	$ 1,050	$ 2,282	$ 2,066

LEASES - Narrative (Details)	Jun. 30, 2024
Lessee, Lease, Description [Line Items]
Renewal term	5 years
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year 2 months
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	11 years

LEASES - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
2024 (6 months remaining)	$ 1,640
2025	2,892
2026	2,169
2027	1,844
2028	1,762
Thereafter	11,884
Total lease obligation	22,191
Less: Imputed interest	(5,359)
Total lease liabilities	16,832
Less: Current lease liabilities	(2,376)	$ (2,252)
Total non-current lease liabilities	$ 14,456	$ 15,655

INCOME (LOSS) PER SHARE - Schedule of Computation of Basic and Dilutive Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Net income (loss)	$ (11,057)	$ (9,634)	$ 2,844	$ (2,912)	$ (20,691)	$ (67)
Weighted-average number of common shares - basic (in shares)	157,227,855		152,481,470		156,632,263	152,398,273
Dilutive effect of securities (in shares)	0		278,618		0	0
Weighted-average number of common shares - diluted (in shares)	157,227,855		152,760,088		156,632,263	152,398,273
Income (loss) per common share – basic (in usd per share)	$ (0.07)		$ 0.02		$ (0.13)	$ 0
Income (loss) per common share – diluted (in usd per share)	$ (0.07)		$ 0.02		$ (0.13)	$ 0

INCOME (LOSS) PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	10,106,808	9,411,551	10,106,808	9,690,169
Outstanding options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	4,523,486	7,012,707	4,523,486	7,012,707
Outstanding restricted share units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	5,583,322	2,398,844	5,583,322	2,677,462

INCOME (LOSS) PER SHARE - Narrative (Details) - BAT Group	Nov. 14, 2022 $ / shares
Line of Credit Facility [Line Items]
Convertible ownership percentage	19.90%
Conversion price (in CAD per share)	$ 2.00

SHARE-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)			0
Options granted, weighted average grant-date fair value (in usd per share)			$ 0	$ 0.38
Options exercised (in shares)			0	0
Fair value of shares vested			$ 946	$ 872
Share-based compensation expense	$ 237	$ 624	1,079	$ 999
Unrecognized share based compensation expense	$ 2,776		$ 2,776
Unrecognized share based compensation expense, period for recognition			2 years 2 months 1 day
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Prescribed service period			4 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years

SHARE-BASED COMPENSATION - Schedule of Principal Inputs Used in Valuation of Awards Issued (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	88.80%
Risk-free interest rate	3.40%
Expected dividend yield	0.00%
Value of underlying share (in usd per share)	$ 0.36
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 6 months

SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Number of Options
Outstanding at the beginning of the period (in shares)	5,780,134
Granted (in shares)	0
Exercised (in shares)	0	0
Forfeited (and expired) (in shares)	(1,256,648)
Outstanding at the end of the period (in shares)	4,523,486		5,780,134
Exercisable/vested (in shares)	3,442,986
Weighted- Average Exercise Price per Option
Outstanding at the beginning of the period (in usd per share)	$ 0.83		$ 0.75
Granted (in usd per share)	0	$ 0.38
Exercised (in usd per share)	0
Forfeited (and expired) (in usd per share)	0.50
Outstanding at the end of the period (in usd per share)	0.83		$ 0.75
Exercisable/vested (in usd per share)	$ 0.89
Weighted- Average Remaining Contract Term (in years)
Outstanding balance	7 years 11 months 8 days		8 years 6 months 21 days
Exercisable/vested	7 years 8 months 8 days
Aggregate Intrinsic Value
Outstanding balance	$ 0		$ 0
Exercisable/vested	$ 0

SHARE-BASED COMPENSATION - Schedule of Restricted Stock Units (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of Shares
Outstanding at the beginning of the period (in shares) \| shares	7,250,766
Granted (in shares) \| shares	3,021,276
Forfeited (in shares) \| shares	(898,685)
Vested (in shares) \| shares	(3,162,676)
Shares withheld upon vesting (in shares) \| shares	(627,359)
Outstanding at the end of the period (in shares) \| shares	5,583,322
Weighted- Average Grant Date Fair Value
Outstanding at the beginning of the period (in usd per share) \| $ / shares	$ 0.31
Granted (in usd per share) \| $ / shares	0.21
Forfeited (in usd per share) \| $ / shares	0.24
Vested (in usd per share) \| $ / shares	0.30
Shares withheld upon vesting (in usd per share) \| $ / shares	0.49
Outstanding at the end of the period (in usd per share) \| $ / shares	$ 0.26

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 46	$ 0	$ 62	$ 0
Effective tax rate	(0.20%)	0.00%	(0.20%)	0.00%

RELATED PARTY TRANSACTIONS (Details) $ in Thousands					3 Months Ended		6 Months Ended		12 Months Ended
RELATED PARTY TRANSACTIONS (Details) $ in Thousands	Jun. 21, 2024 USD ($)	May 01, 2023 USD ($) monthly_installment	Mar. 02, 2021 USD ($)	Nov. 30, 2020 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2021 USD ($)	Apr. 06, 2023 USD ($) shares
Related Party Transaction [Line Items]
Purchase option			$ 8,000						$ 8,000
Revenue					$ 12,289	$ 16,006	$ 24,413	$ 33,016
DeFloria, LLC
Related Party Transaction [Line Items]
Common units (in shares) \| shares										400,000
DeFloria, LLC \| British American Tobacco
Related Party Transaction [Line Items]
Preferred units (in shares) \| shares										200,000
Capital contributed										$ 10,000
Payment for convertible debt							5,000
DeFloria, LLC \| AJNA Biosciences
Related Party Transaction [Line Items]
Common units (in shares) \| shares										400,000
Payment for convertible debt							2,000
Related Party
Related Party Transaction [Line Items]
Secured promissory note				$ 1,000
Note receivable interest rate		8.00%		3.25%
Related Party \| Notes Receivable
Related Party Transaction [Line Items]
Number of monthly installments \| monthly_installment		36
Other assets		$ 170			$ 99		$ 99
Related Party \| Consulting Agreement
Related Party Transaction [Line Items]
Bi-weekly fee	$ 6